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Background: With 1.1 million new cases diagnosed annually worldwide and 
4500 to 5000 in Finland, prostate cancer (PC) is, in developed countries, the 
most common non-cutaneous cancer in men. It is a highly heterogenous 
disease with great variability in its clinical course. Men diagnosed with PC 
are stratified into risk groups, reflecting how aggressive the disease is and 
how actively it should be treated and monitored. Low-risk PC is generally 
indolent and often requires no curative treatment. Active surveillance (AS) is 
its primary treatment option, whereas high-risk PC, at the opposite end of 
the disease spectrum, offers significant risk for local advance and metastasis; 
radical treatment is therefore necessary. Despite treatment, high-risk PC still, 
however, poses a risk for cancer recurrence and even risk of death. 
Intermediate- and high-risk PC are generally treated with radical 
prostatectomy (RP) or radiation therapy. 
Accurate risk stratification is essential for choosing proper treatment. 
Currently, stratification is based on diagnostic prostate biopsies, the patient’s 
prostate-specific antigen (PSA) level, and clinical stage. This current 
stratification system has well-established limitations. The biggest uncertainty 
stems from prostate biopsies. The biopsies are performed in a schematic 
manner with ultrasound guidance, which does not, however, distinguish 
possible tumors from surrounding benign tissue. Current risk stratification 
also ignores prostate magnetic-resonance imaging (MRI). Better strategies 
for the diagnosis and risk stratification of PC are thus necessary.  
Study I: Prostate biopsy is one of the most common urological out-
patient procedures. The procedure is carried out via the rectum and carries a 
substantial risk for complications, such as infection, bleeding, and pain. The 
most severe complications involve infections, an alarming rising trend in 
incidence of which has occurred globally in recent years. In Study I, we 
retrospectively evaluated the incidence of bacteremic post-biopsy 
complications in the Helsinki and Uusimaa hospital district during 2005-
2013. Annual incidences were calculated by combining databases of all 
prostate biopsies and positive blood cultures during this period. Clinical data 
on the bacteremic patients allowed exploration of possible risk factors for 
infections.  
Study II: The current standard prostate biopsy procedure involves 
taking 12 biopsy cores in a prespecified pattern, without knowledge of 
possible tumor location. Until the introduction of prostate MRI, biopsies 
were the only tool with which to plan curative therapies in detail. PC is often 
a multifocal disease, with several separate tumor foci in the prostate. In 
Study II we retrospectively investigated in RP specimens the performance of 
12-core prostate biopsies in predicting tumor location and extent. We also 
analyzed tumor morphologies with emphasis on clinically significant PC and 
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the index tumors. This was achieved by charting all tumors in the RP 
specimens of 96 men treated with laparoscopic robot-assisted RP at our 
institution between 2009 and 2010. Detailed information on tumor locations 
and morphologies was compared with data from diagnostic biopsies.     
Study III: AS entails close monitoring of patients and relies heavily on 
serial PSA measurements and repeat biopsies. This monitoring is 
increasingly complemented with prostate MRI. Study III was a prospective 
study investigating the value of prostate MRI in the follow-up of AS patients. 
In 2009-2011, 80 men underwent prostate MRI after being on AS for one 
year and before receiving their first follow-up biopsies. MRI findings were 
compared with clinical and pathological parameters to assess whether MRI 
added any value to the standard follow-up.   
Study IV: Novel tools for better prediction of PC patients’ outcomes are 
being actively explored, with much attention to PC tissue biomarkers. In 
Study IV, we retrospectively analyzed 358 men treated with RP between 1983 
and 1998 at Helsinki University Hospital and 457 men operated on between 
2000 and 2005 at Turku University Hospital. The expression of each of three 
PC tissue markers–ERG, PTEN, and AR–were analyzed by constructing 
tissue microarrays from the patients’ RP samples. We explored the 
association of marker expression with clinical outcomes: requirement for 
secondary therapy after RP, disease-specific survival (DSS), and overall 
survival (OS). 
Main results and conclusions: A 2.4-fold increase in the annual 
incidence of post-biopsy bacteremic complications emerged over the study 
period, with no clinical risk factor for developing bacteremic complications. 
Recent international travel was associated with development of an infectious 
complication by a fluoroquinolone-resistant organism. Strategies to avoid 
unnecessary biopsies and reduce biopsy-related infections call for 
development (I). Twelve-core prostate biopsies predicted location and extent 
of tumors in RP specimens unreliably, which makes them a poor tool for 
detailed planning of radical or focal therapies. Analysis of significant tumors 
and index tumors revealed that positive surgical margins and extraprostatic 
extension at RP were mostly caused by the index tumor. The index tumor can 
thus be chosen based on dedifferentiation instead of on tumor size (II). 
Prostate MRI added no value to the standard follow-up of AS patients. To 
perform reliably as a diagnostic and follow-up tool, prostate MRI should be 
performed and reported based on prespecified and standardized protocols 
(III). Loss of PTEN expression led to shorter DSS times and shorter 
secondary-therapy-free survival after RP. The poorest outcomes were for 
patients with PC samples negative for both ERG and PTEN expression and 
with strong AR expression. PTEN loss appears to be a strong driver for disease 
progression, and its performance as a prognostic tool should be further studied 




Prostate cancer (PC) is the most common cancer in men in the Western world 
(Torre et al. 2015), but is still, in many ways, a poorly characterized disease. 
The older the man, the more likely he is to be diagnosed with PC (Sakr et al. 
1994), and men of African heritage are at higher risk (McGinley et al. 2016). 
Genetics also play a major role: roughly half of an individual’s risk for PC is 
the result of advancing age and environmental factors, but the remaining half 
stems from genetic factors (Lichtenstein et al. 2000, Mucci et al. 2016). 
Despite this, no genetic tests can as yet aid in identifying at-risk men at 
population level. Age, race, and genetics are all unamenable factors, with no 
firmly-established environmental or life-style factors exist that men can avoid 
to lower their PC risk. 
One unanswered question is how to properly screen for PC. PSA-based 
screening has been tested and studied in two large prospective trials in Europe 
and the USA (Schröder et al. 2014, Pinsky et al. 2017), but with conflicting 
results. PSA-based screening has been able to prevent deaths from PC 
(Schröder et al. 2014), but at such a high cost of over-detection and over-
treatment that general screening for unselected men is not recommended. 
Unorganized or opportunistic PSA-based screening is, however, still widely 
prevalent in clinical practice, and the problem of over-detection and over-
treatment of PC remains unsolved. In 2010-2014 in Nordic countries, the 
proportion of men dying from PC compared to men diagnosed with PC was 
23% (NORDCAN 2017). This reflects the slow natural progression of PC and 
the relevance of competing causes of death for such men. Nevertheless, in 2014 
in Finland, PC was still the second-most likely cancer to kill men (Finnish 
Cancer Registry 2016) 
When a man presents with a PSA value higher than considered normal for 
his age, the next step is to decide whether to proceed with the diagnostic work-
up. There are no safe cut-off values below which we can be sure that PC, even 
potentially lethal PC, does not occur (Thompson et al. 2007). The decision to 
proceed with further work-up such as prostate biopsies is therefore hardly ever 
straightforward. Besides the baseline PSA value, other factors need to be 
considered as well, such as patient age, comorbidities, assumed life 
expectancy, possible family history of PC, and personal preferences. A 
straightforward approach would be simply to take biopsies from all men who 
present with elevated PSA values, but that approach would not only be fraught 
with complications, but also expose men to an unnecessary risk of 
overdiagnosis. The biopsy procedure carries a risk for bleeding, pain, and most 
importantly, infectious complications that can be catastrophic (Borghesi et al. 
2017). Traditional prostate biopsies have several limitations, of which the most 
important is their under-estimation of disease extent and grade (Epstein et al. 
2012). Sampling all patients with elevated PSA in a non-organized setting 
 
11 
would also result in a substantial number of men overdiagnosed with low-
grade, clinically insignificant PC with an inherent risk for overtreatment, 
causing an undue burden upon the patient and health-care system. 
PC is a heterogenous disease. Most PCs progress slowly and most likely 
cause no harm during a patient’s lifetime (Lu-Yao et al. 2009). Some PCs, on 
the other hand, are irrefutably aggressive, recur despite radical therapies 
(Stattin et al. 2016, Pompe et al. 2017), and progress to a metastatic and lethal 
stage. The challenge is in properly identifying which patients harbor 
“benevolent” and which patients aggressive disease. Current tools for 
characterizing PC are largely inadequate, especially regarding the proper 
assessment of disease aggressiveness. The current risk stratification is based 
on histopathological evaluation of PC needle biopsies, where a Gleason score 
(Gleason 1966) is assigned for the disease. This score is used in risk assessment 
along with PSA level at diagnosis, clinical disease stage, and, for low-grade 
disease, number of biopsies positive for PC (Mohler et al. 2016, Mottet et al. 
2017). This risk stratification guides the choice of treatment, but the varying 
outcomes of patients within risk groups reflect how imperfectly these risk 
groups actually predict the course of the disease (Beauval et al. 2016a, 2016b, 
Carlsson et al. 2016). When assigning low-risk patients to AS, 50 to 70% of 
these patients will eventually end up having definitive therapies, such as 
radical prostatectomy (RP) or radiation therapy (RT) (Bokhorst et al. 2016b). 
After surgery or RT, 27 to 53% of patients will have disease recurrence (Mottet 
et al. 2017), and some will develop metastases and eventually die from PC. 
Attempts are ongoing to overcome these shortcomings in risk stratification. 
Magnetic-resonance imaging (MRI) of the prostate holds great promise for 
improving the diagnostic process. Performance of prostate MRI before taking 
biopsies can potentially select the right patients for the procedure (Ahmed et 
al. 2017) and MRI-targeted biopsies appear to be more accurate in terms of 
determining disease location and aggressiveness (Siddiqui et al. 2015). A new 
prognostic grouping of histological cancer grades–grade grouping–aims to 
predict disease outcomes better than conventional Gleason scoring, mainly for 
the most frequent Gleason score 7 group (Epstein et al. 2016b). Research 
efforts in the field of PC biology have revealed some key genetic phenomena in 
disease progression that have given rise to potential biomarkers (Bostrom et 
al. 2015). Biomarkers would, ideally, reflect true disease aggressiveness and 
could be used in conjunction with conventional tools to estimate patients’ risk 
for harboring a more aggressive disease than otherwise suspected. 
This thesis focuses on the challenges and limitations of current diagnostic 
and predictive tools in assessing localized PC and aims to offer insight into 
areas with room for improvement. 
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2 REVIEW OF THE LITERATURE 
2.1 EPIDEMIOLOGY OF PROSTATE CANCER 
With 1.1 million new cases diagnosed in 2012, PC is the fourth most common 
cancer worldwide among both sexes, and the second-most common cancer in 
men. PC accounts for 8% of all new cancer cases globally and for 15% of new 
cancers in men. A marked difference occurs in PC incidence rates between 
developed and developing countries, with 68% of PC diagnoses in developed 
countries with only 17% of the world’s male population. With an age-
standardized rate (ASR) of 69.5 per 100 000, PC is, excluding skin cancers, 
the most common cancer of Western men (Torre et al. 2015). According to 
Cancer Research UK, about one man in eight in the UK and according to the 
American Cancer Society, one man in seven in the USA will be diagnosed 
with PC during their lifetime. 
 
Figure 1 Estimated worldwide age-standardized incidence rates of prostate cancer in 2012. 
Reprinted with permission from the World Health Organization. 
Globally improved standards of living and health awareness have led to an 
increased life expectancy associated with increasing PC incidence and 
prevalence. Improved health awareness has also led to unorganized screening 
for PC by PSA testing (Nordstrom et al. 2016). Historically, the Food and Drug 
Administration (FDA) approval of the PSA test in 1986 led to a sharp rise in 
PC diagnoses in the USA, reaching its peak five years later in 1992. This was 
succeeded by a steep decline, after which, incidence rates steadily started 
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increasing again. Similar trends have later been observable in many other 
countries where PSA-based detection has been extensive.  
PC mortality rates and PC incidence rates differ markedly (Figure 2).  
Many countries have seen peak mortality rates in the 1990’s, after which they 
have rapidly decreased. The diminishing mortality of PC is to some degree 
due to better therapies, but likely to a greater extent due to the extensive use 
of PSA, which leads to PC detection at earlier, asymptomatic, and localized 
stages. Most men diagnosed with PC will therefore survive despite their 
cancer, which is evident in the 10-fold incidence rates compared with 
mortality rates (Figure 2). This places great pressure on health-care systems 
to appropriately calibrate their diagnostic processes, in addition to adjusting 
their thresholds for radical therapies, to avoid overtreating and causing PC 
patients excessive harm. 
2.2 ETIOLOGY AND RISK FACTORS FOR PROSTATE 
CANCER 
2.2.1 ADVANCING AGE 
Global PC incidence rates vary greatly (Figure 1), and PC is strongly 
associated with advancing age. It can, to some extent, be considered a natural 
occurrence in the aging process. In their seminal autopsy study from 1994, 
Sakr and co-workers found cancer foci in 2%, 29%, 32%, 55%, and 64% of 
prostates of men over 20, 30, 40, 50, and 60 years of age (1994). More-recent 
studies have shown that, at autopsy, 43.9% of men over age 70 harbored 
cancer foci in their prostates (Zlotta et al. 2013) and, in a review of 19 
autopsy studies including over 6000 men, 22% of men aged 50-59, 29% aged 
60-69, 34% aged 70-79, and 43% of men over 80 had undiagnosed PC at the 
time of death (Jahn et al. 2015). Advancing age is therefore a considerable 
risk factor for PC.  
2.2.2 ETHNICITY 
The highest PC rates are encountered in developed high-income regions with 
long life expectancies, such as Australia, New Zealand, North America, and 
Western and Northern Europe. Incidences are also relatively high in some less 
affluent regions such as the Caribbean, sub-Saharan Africa, and in South 
America. The lowest incidences are encountered in Eastern and South-Central 
Asia (Ferlay et al. 2015). This global variance in incidence may be explained by 
economic differences, varying practices of PSA testing and the accompanying 
biopsies, and by various PC risk factors.  
Review of the literature 
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Figure 2 Age-standardized (world) prostate-cancer incidence (top) and mortality (bottom) 
trends. Mortality trends have been smoothed using three years’ average. Source: 
International Agency for Research on Cancer (IARC). Website accessed on 11.7.2017. 
Reprinted with permission from the World Health Organization. 
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Race-associated differences occur in PC development, with men of African 
heritage being at highest risk. The world’s highest incidences are on the 
Caribbean island of Martinique, with Trinidad and Tobago and Barbados also 
in the top five (Ferlay et al. 2015). Caribbean islands, along with Brazil and the 
USA, are the countries outside Africa with the highest proportions of African 
populations, as reflected in their corresponding high PC incidence rates 
(Figure 1). PC incidence is also highest among men of African heritage in the 
USA (McGinley et al. 2016). The lowest PC incidences are in Asian men (Center 
et al. 2012). This was also evident in the marked diferences between the 
prevalence of PC at time of death in men of different races: in the age group 
70-79, African-American men had the highest prevalence of PC at 51%, 
Caucasian and European men were at 36%, and the lowest prevalence, 21%, 
was in Asian men (Jahn et al. 2015). Research into the genetic phenomena 
underlying these differences is ongoing. 
2.2.3 GENETICS 
Approximately 100 genes have been identified that raise an individual’s risk 
for PC (Ciccarese et al. 2017), most importantly germline mutations in the 
tumor-suppressor breast cancer 1 and 2 genes, BRCA1 and BRCA2. BRCA2 
mutations confer a 5-9-fold risk for developing PC, compared to that of men 
without the mutation, but the risk associated with BRCA1 mutations, at 
approximately 4-fold, is less pronounced (Alanee et al. 2014, Eeles et al. 2014). 
Such mutations are also associated with worse PC outcomes (Alanee et al. 
2014). The prevalence of BRCA2 mutations in one general PC cohort was, 
however, only 1-2% (Kote-Jarai et al. 2011), so testing all PC patients for this 
mutation would be unlikely to prove beneficial.  
A family history of PC may suggest an inherited risk. Having one affected 
first-degree relative raises the risk of PC 2.5-fold and having two or more 
affected first-degree relatives raises it 5- to 11-fold (Steinberg et al. 1990, 
Brandt et al. 2010). Moreover, having a father diagnosed with PC raises an 
individual patient’s risk of PC by 2-fold, whereas a brother’s PC raises the risk 
by 3-fold (Zeegers et al. 2003, Brandt et al. 2010). Carter and co-workers have 
suggested considering PC as hereditary, when there are either three or more 
affected members in a nuclear family, PC in three successive generations, or 
two or more individuals diagnosed with PC before the age of 55 (Carter et al. 
1993). By this definition, 3-5% of PC cases could be classified as hereditary 
(Bratt 2000). A recent report from the Nordic Twin Study of Cancer group 
revealed significant excess familial risk for PC. The estimate of heritability, i.e. 
how much of an individual’s risk for cancer results from genetic factors, has 
been as high as 57% (Mucci et al. 2016). An earlier study, also on a Nordic twin 
cohort, found the estimate to be 42% (Lichtenstein et al. 2000). 
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2.2.4 ENVIRONMENTAL AND LIFE-STYLE FACTORS 
Age, ethnicity, and genetics–all nonmodifiable factors–are the only confirmed 
risk factors for PC. Myriads of environmental and life-style factors that may 
contribute to PC development under investigation, often with conflicting 
results (Giovannucci et al. 2007). This is presumably because of the disease’s 
heterogeneous nature. Another speculation is that instead of being a precursor 
state, early-detectable indolent PC could possibly be a separate disease entity 
from lethal PC, with different etiologies and risk factors (Jahn et al. 2015).  
The contemporary Western lifestyle, i.e. sedentary with a high-calorie diet, 
leading often to high cholesterol and diabetes, is speculated to play a role in 
PC development. Despite Japan’s being a high-income country, PC is still far 
less prevalent in Japan than in Europe or North America. This fact is 
attributable to differing lifestyles, mainly dietary differences. The role of the 
environment has been highlighted in studies on Japanese immigrants in 
Hawaii which demonstrated that, because of a change in environment, PC 
incidence in first- and in second-generation immigrants have risen rapidly 
(Kolonel et al. 2004). Gradual adoption of the Western lifestyle is also 
suggested to explain the current steady rise in PC incidence in Japan, 
Singapore, and Thailand–countries where PSA testing is traditionally 
uncommon (Center et al. 2012).  
High body-mass index seems to have a complex effect on risk for 
developing PC: it has been associated with increased risk for PC (Nunez et al. 
2017) and with more advanced cancer (World Cancer Research Fund 
International: Continuous Update Project 2014), but on the other hand, 
associated with a reduction in risk for localized PC (Discacciati et al. 2012). 
Similarly, taller height has been clearly associated with development of lethal, 
but not of indolent, PC, suggesting that the two disease forms are distinct 
biological entities (Giovannucci et al. 2007).  
Alcohol consumption is generally not considered to raise the risk for PC, 
although evidence to counter this is gradually accumulating (Rota et al. 2012, 
Dickerman et al. 2016). It is unclear whether cigarette smoking is a risk factor 
(Huncharek et al. 2008, Watters et al. 2009) as it has been related to a higher 
risk for lethal disease, but not indolent PC (Giovannucci et al. 2007) Long-
standing inflammation may predispose to development of PC, and evidence 
exists from meta-analyses that suggests gonorrhea to be associated with 
increased risk for PC (Caini et al. 2014, Lian et al. 2015). The role of other 
sexually-transmitted diseases is less clear. 
2.3 DIAGNOSING PROSTATE CANCER 
2.3.1 PSA AND PSA-BASED SCREENING 
PC rarely causes symptoms before it has progressed to an advanced stage. PC 
is, in fact, most often diagnosed at an earlier, asymptomatic stage solely by an 
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elevated PSA. A patient with advanced disease may suffer from lower urinary 
tract symptoms (LUTS): increased voiding frequency and urgency, nocturia, 
hematuria, and even urinary retention. Metastatic disease may present as 
skeletal pain, neurological symptoms, anemia, or general malaise. The process 
of diagnosing PC, initiated by either PSA screening or, rarely, PC symptoms, is 




Figure 3 PSA-based and symptom-based detection of prostate cancer (PC). PSA=prostate-
specific antigen, DRE=digital rectal examination, w=with, w/o=without, MRI=magnetic-
resonance imaging, LUTS=lower urinary tract symptoms, TRUS=transrectal ultrasound  
A first-line method of diagnosing PC is the PSA blood test. PSA is a 
kallikrein-like serine protease produced and excreted by the prostate. It is 
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reasonably specific to the prostate, and higher levels are associated with a 
greater likelihood of PC: at level < 1 ng/ml, the likelihood is 1%, at 2-4 ng/ml 
15%, at 4-10 ng/ml 25%, and at > 10 ng/ml > 50% (The Finnish Medical 
Society Duodecim 2014). PSA’s usefulness as a diagnostic test is, however, 
hampered by its susceptibility to increasing for benign reasons, such as benign 
prostatic hyperplasia, inflammation, ejaculation, and prostatic manipulations, 
among others. Elevated PSA is therefore not specific to PC. No safe cut-off 
values exist, below which no significant PC occurs. This fact was demonstrated 
in the Prostate Cancer Prevention Trial, where, in the control arm, even at a 
PSA level ≤ 0.5 ng/ml 6.6% of participants had PC, and 12.5% of those men 
had high-grade PC, defined as Gleason score ≥ 7 (Thompson et al. 2004). 
Reference PSA values are age-adjusted to account for the natural rise in PSA 
resulting from benign prostatic growth. Currently, the European Association 
of Urology (EAU) guidelines consider risk for PC to be elevated with a PSA > 1 
ng/ml at age 40, and with a PSA > 2 ng/ml at 60 (Mottet et al. 2017). 
Presently, no nation has a national screening program for PC, even though 
so-called opportunistic screening by PSA testing is quite prevalent in many 
Western countries. PSA testing appears, at first glance, to be an inexpensive 
and easy way to screen for PC, and the concept has therefore been tested 
globally in several large-scale studies. The Prostate, Lung, Colorectal, and 
Ovarian Cancer Screening Trial demonstrated no mortality benefit from 
organized PSA screening at 15 years (Pinsky et al. 2017), while the European 
Randomised study of Screening for Prostate Cancer found that, after 13 years, 
even though PSA screening reduces mortality from PC, the benefit comes at a 
cost of high over-detection and over-treatment (Schröder et al. 2014). PSA 
screening is thus not currently recommended at population level, although the 
synthesis of a 2014 Cochrane review and the American Urological Association 
guidelines state that PSA screening in men aged 55-69 may be considered after 
shared decision-making by the patient and doctor (Carter 2013, Hayes, Barry 
2014). The EAU guidelines on PC also recommend an individualized risk-
adapted strategy for early detection instead of systematic PSA-based 
screening. Early detection can be discussed with well-informed men who have 
a good performance status and at least 10-15 years’ life expectancy, when they 
are considered as having elevated PC risk: age over 50, age over 45 with a 
family history of PC or African heritage, or a baseline PSA of > 1 ng/ml at 40 
years or > 2 ng/ml at 60 (Mottet et al. 2017). 
Because of PSA’s poor specificity in predicting PC, several other blood and 
urine tests have been developed over the years with the aim of helping to select 
those men at increased risk for PC who thus are candidates for further 
diagnostic work-up. The ratio of free to total PSA (%fPSA) can be useful for 
men with a PSA between 4 and 10 ng/ml and negative digital rectal 
examination (DRE) (Mottet et al. 2017). PC was detected in 56% of such men 
at %fPSA < 0.10, but in only 8% with %fPSA > 0.25 (Catalona et al. 1998).  
Reviews looking into the performance of urine-marker PCA3, a kallikrein 
panel called the 4K Score, and The Prostate Health Index, which incorporates 
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calculation of PSA, free PSA, and the [2]pro-PSA fraction, report that use of 
these tests would reduce unnecessary prostate biopsies and the diagnosis of 
insignificant PC (Bratt et al. 2015, Loeb et al. 2016). Currently, the widespread 
use of these tests is limited by their poor availability, high costs, and, in the 
case of the 4K Score, lack of FDA approval. The STHLM3 model, which 
includes a combination of plasma protein biomarkers and a panel of 232 
single-nucleotide polymorphisms, combined with traditional PSA and clinical 
parameters, has been tested in a prospective setting in Sweden and seems to 
be a promising model for improving the specificity of PSA-based screening for 
PC (Grönberg et al. 2015). STHLM3, however, still lacks validation in non-
Swedish populations. 
2.3.2 PROSTATE BIOPSIES 
2.3.2.1 Performing prostate biopsy 
After DRE of the prostate and blood tests, the next step in the diagnostic work-
up is taking prostate biopsies. Biopsies are essential for establishing cancer 
diagnosis and grade, but also aid in assessing the location and extent of the 
disease. Prostate biopsy is usually performed as an out-patient procedure, 
under local anesthesia, and most often via the transrectal route by a urologist. 
The procedure is performed with ultrasound (US) guidance, so in many 
countries the procedure may also be performed by a radiologist. US serves 
mainly for visualizing the prostate and its outlines and for guiding the biopsy 
needles. The resolution of US is rarely sufficient for visualizing PC, which 
means that standard prostate biopsies are obtained as systematic random 
biopsies. The most common biopsy scheme entails 12 cores from the 
peripheral prostate, from both sides: four from the bases, four from the mid-
gland, and four from the prostatic apex (Gore et al. 2001) (Figure 4). 
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Figure 4 A. Taking prostate biopsies with transrectal ultrasound guidance. B. 12-core biopsy 
scheme, four biopsies each from the base, middle, and apex of the prostate. PZ=peripheral 
zone, TZ=transitional zone, U=urethra. (Illustration by Kristiina Tammisalo) 
Sampling the prostate is an invasive procedure, with common side-effects. 
The most common adverse outcomes are hematuria, hematospermia, rectal 
bleeding, and pain, which are most often self-limiting and only rarely require 
further medical attention. The procedure can, however, also cause major harm 
to the patient, if he develops a major infectious complication, the most severe 
form of which is potentially life-threatening septicemia. The patient must be 
informed of the potential risks associated with the procedure before 
proceeding with prostate biopsies. 
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2.3.2.2 Gleason score and Grade grouping 
Presently, the prevailing grading system is the tissue-architecture-based 
Gleason grading system (Gleason 1966) with major consensus modifications 
in 2005 (Epstein et al. 2005), 2010 (Epstein 2010), and 2014 (Epstein et al. 
2016a). The modified grading system assigns the PC a Gleason score of 2 to 10, 
based on the prevalence of individual grade patterns. A new prognostic grade 
grouping system was launched in 2014 in a consensus meeting of the 
International Society of Urological Pathology. The new classification gives 
scores from 1-5, with Gleason patterns ≤ 3+3, 3+4, 4+3, 4+4/3+5/5+3, and 
4+5/5+4/5+5 constituting grade groups 1, 2, 3, 4, and 5. This new grouping 
system aims to better reflect the different prognoses between the groups. It 
also aims to deemphasize the seriousness of Gleason score ≤ 6 cancers – grade 
group 1, on a scale of 1-5, as being easier for treating physicians and patients 
to accept as a low-risk disease, rather than Gleason score 6, on a scale of 2-10. 
Grade grouping also distinguishes subclasses in the most prevalent Gleason 
score 7 group, among other changes. This new grouping has been formally 
accepted by the World Health Organization in 2016 and for now, the Grade 
group should be reported in conjunction with the Gleason score (Epstein et al. 
2016a). 
2.3.2.3 Current 12-core biopsy technique 
Before ultrasound (US) guidance became common, the first prostate biopsies 
were taken with only finger guidance, and with urologists taking as many cores 
as considered necessary. In their landmark study in 1989, Stamey and co-
workers reported improved cancer detection rates by performing random 
systematic biopsies instead of biopsies exclusively directed at suspicious areas 
(Hodge et al. 1989). This approach, later dubbed the Stamey sextant protocol, 
involved sampling the prostate in a systematic fashion: one parasagittal core 
each from the base, middle, and apex of the prostate, from each lobe and with 
US guidance. The sextant protocol was later extended to include more laterally 
directed cores and gradually evolved into the current 12-core biopsy scheme 
that has been in use for practically the last two decades (Levine et al. 1998, 
Gore et al. 2001). The optimal number of cores needed to maximize cancer 
detection, with the procedure still being tolerable for the patient, has been 
studied extensively, with the 12-core scheme remaining an acceptable 
compromise (Eichler et al. 2006, De Laet et al. 2009, Ghafoori et al. 2013, 
Scattoni et al. 2014). 
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2.3.2.4 Detection of prostate cancer by random biopsies  
Standard prostate biopsies have several well-known limitations (Figure 5). 
 
Figure 5 A. Random biopsies missing a significant tumor. B. Random biopsies detecting 
small, low-grade tumors. C. Inaccuracy in determining tumor location. Tumor assumed to be 
from the base of the prostate when in reality it is from the middle. (Illustrations by Kristiina 
Tammisalo) 
As the biopsies randomly sample the entire prostate, the test may result in 
both underdiagnosis of clinically significant disease and overdiagnosis of 
indolent, clinically insignificant PC. Transrectal biopsies are also technically 
limited in estimating disease location. This has been demonstrated in many 
studies reporting the discordance in tumor location between biopsy and RP 
specimens (Schulte et al. 2008, De Laet et al. 2009, Iremashvili et al. 2012, 
Washington et al. 2012).  
As a first-line test for detecting PC, transrectal random biopsies perform 
poorly. Initial biopsies may have detection rates of 28-70% (Meng et al. 2003, 
Presti Jr. 2003, de la Taille et al. 2003, Elabbady et al. 2006, Yuasa et al. 2008, 
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Serag et al. 2011, Zaytoun et al. 2011a, Aganovic et al. 2012). This wide range 
is due to heterogeneity in study cohorts and in biopsy indications. 
Consequently, after a first round of negative biopsies, if PC is still suspected, 
up to one-third of patients will have PC detected in repeat biopsies (Fleshner 
et al. 1997, Presti Jr. 2003, Scattoni et al. 2007, Yuasa et al. 2008, Campos-
Fernandes et al. 2009, Zaytoun et al. 2011b). After a second round of biopsies, 
however, the detection rates, especially for clinically significant cancers, 
decrease markedly. If, after two rounds of negative biopsies, PC is still 
suspected, then a change in diagnostic strategy is therefore the general 
recommendation (Djavan et al. 2007, Zaytoun et al. 2011a).  
In the situation of repeated negative prostate biopsies and persistent 
suspicion of PC, an intermediate step in the diagnostic work-up has 
traditionally been saturation biopsies, generally defined as obtaining > 20 
cores. A transperineal approach to saturation biopsies is possible, but as it 
necessitates spinal anesthesia, it is thus more arduous. The advantage of the 
transperineal approach over the transrectal route, is, however, better access to 
the apex and anterior prostate. Saturation biopsies have become less popular 
with the advance of MRI targeting. Currently, the shift towards earlier 
incorporation of alternative diagnostic methods is strong, as an alternative to 
automatically repeating the biopsies. The EAU Prostate Cancer Guidelines 
recommend performing prostate MRI before repeat biopsies. The repeat 
biopsy procedure should then preferably include targeting of MRI-visible 
lesions in addition to systematic biopsies (Mottet et al. 2017). 
Some limitations of traditional systematic prostate biopsies are inherent to 
the biopsy technique. The procedure’s randomized nature and the inability to 
visualize tumors with US explain some of the sampling error. Large tumors, 
either exceptionally hypoechoic on US or palpable on DRE, can specifically be 
targeted, but otherwise the needles are placed in the tissue at random. The 
transrectal route also makes accessing the anterior prostate difficult (Bott et 
al. 2002). Sampling the prostatic apex requires angling the rectal probe and 
biopsy needle to a degree that is uncomfortable or even painful for the patient, 
leading to apical tumors’ often being missed (Bolenz et al. 2009, Iremashvili 
et al. 2012). In primary biopsies, the peripheral zone, the area in which 68-
85% of PC originates (McNeal et al. 1988, Stamey et al. 1998, Buyyounouski et 
al. 2017), should be targeted (Figure 6). This approach, however, frequently 
misses those tumors deriving from the transitional or central zones.  
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Figure 6 Zonal anatomy of the prostate. By some estimates, the peripheral zone harbors 80-
85% of prostate cancer, the transitional zone 10-15%, and the central zone 5-10% 
(Buyyounouski et al. 2017). Figure reprinted with permission from Nature Publishing Group: 
Nature Reviews Cancer, 2007, Apr;7(4):256-69, De Marzo et al., “Inflammation in prostate 
cancer”. 
2.3.2.5 Treatment planning based on biopsies 
Despite their known limitations, and outside of clinical study settings, 
transrectal systematic biopsies are still the first-line test by which most PC is 
diagnosed. Before prostate MRI and MRI-targeting, prostate biopsies were 
essential in planning the treatment of PC patients. The histopathological 
assessment of disease grade is essential in appropriately assessing the patient’s 
risk group (Table 2). 
     Prostate biopsies may, however, perform less than ideally in evaluating the 
Gleason score. Accounts of mostly upgrading and also of downgrading of the 
Gleason score in comparisons between biopsies and RP specimens are 
numerous. Rates of upgrading of Gleason score at RP range from 14.8-46.6% 
(Elabbady et al. 2006, Reis et al. 2013, Dinh et al. 2015, Khoddami et al. 2016, 
Winters et al. 2016, Herlemann et al. 2017), with downgrading less frequent at 
8.5-19.5% (Reis et al. 2013, Khoddami et al. 2016, Herlemann et al. 2017). This 
problem is in part due to differences in assigning the Gleason score for biopsies 
and RP specimens (Epstein et al. 2012) and in part to the biopsies’ random 
and imperfect discovery of tumors. 
     Prostate biopsies may also underestimate tumor size and extent. This has 
mostly emerged from a situation of minimal cancer core involvement at 
diagnosis and subsequent faulty classification of patients as “low-risk” 
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(Johnstone et al. 2007). Biopsies have indicated the location and laterality of 
the disease inaccurately (Schulte et al. 2008, Abdollah et al. 2011, Pereira et 
al. 2014). Possible explanations are inaccurate needle placement by the 
urologist or errors in processing of the biopsy samples. A 12-core biopsy also 
yields approximately 0.1 g of prostatic tissue for analysis, which would amount 
to less than 1% of, for example, a moderate-size 50-gram prostate. 
Undersampling and missing of tumors is therefore unsurprising. These errors 
may lead to misinformed decisions in treatment planning, such as to perform 
a nerve-sparing RP on the side of the prostate harboring the significant and 
extensive disease.  
     Such inaccuracies involving prostate biopsies in determinination of disease 
grade, extent, and location can currently be somewhat remedied by prostate 
MRI. MRI can either confirm the findings or reveal significant tumors perhaps 
missed by biopsy. 
2.3.2.6 The index tumor and focal therapy (FT) 
Precise and accurate knowledge of tumor characteristics, based on biopsies 
and on MRI applications, is essential in considering FT of PC (Lecornet et al. 
2010, Abdollah et al. 2011, Tseng et al. 2011, Gallina et al. 2012, Washington 
et al. 2012, Kanthabalan, Emberton & Ahmed 2014). FT aims to target all 
clinically significant tumors in the prostate while leaving the rest of the gland 
intact. Among various ways to define PC as “clinically significant,” the 
prevailing definition is a tumor at least 0.5 ml in volume, a Gleason 4 pattern, 
or non-organ-confined disease at RP (Stamey et al. 1993, Kanthabalan, 
Emberton & Ahmed 2014, Kryvenko, Epstein 2016). In 1994, Epstein and co-
workers proposed pretreatment criteria predictive of significant disease: a PSA 
density of ≥ 0.15 ng/ml/g, Gleason grade 4 in biopsies, ≥ 3 biopsy cores 
showing cancer, and ≥ 50% of any biopsy core length with cancer (Epstein et 
al. 1994). These Epstein criteria became widely validated and are still in use 
(Ploussard et al. 2011).   
The concept of an index tumor often arises regarding FT feasibility. 
Autopsy studies and analyses of RP specimens have revealed that PC is most 
often a multifocal disease, which is the rationale supporting whole-gland 
radical therapies. The tumors can also be heterogenous in their degree of 
dedifferentiation, and one hypothesis is that there always exists one primary 
tumor carrying the highest potential for spread and metastasis (Liu et al. 2009, 
Karavitakis et al. 2011, Boyd et al. 2012, Karavitakis et al. 2012, Singh et al. 
2013), the index tumor. Currently, the prevailing practice is to designate the 
largest tumor as the index tumor (Bott et al. 2010, Mouraviev et al. 2011, 
Kozminski et al. 2014), although the index tumor may in fact be the most 
dedifferentiated one or the one causing extraprostatic extension. Most often 
the largest tumor is the one that also exhibits these unfavorable characteristics 
(Karavitakis et al. 2011, Huang et al. 2014a). 
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2.3.3 PROSTATE MRI 
2.3.3.1 Performing and reporting of prostate MRI 
MRI has recently gained substantial attention in the diagnostic work-up of PC. 
Although first developed in the 1980’s, prostate MRI became a routine practice 
only when functional imaging was developed, offering information on prostate 
tissue physiology as well as anatomy. The current gold standard in prostate 
imaging is multiparametric MRI (mpMRI). The European Society of 
Urogenital Radiology published guidelines in 2011 regarding the technical 
performance of mpMRI and proposed a structured reporting system to help 
minimize variation in interpreting the images and reporting the findings 
(Barentsz et al. 2011). This Prostate Imaging - Reporting and Data System (PI-
RADS) was updated in 2015 into the current reporting system: PI-RADS 
version 2 (Weinreb et al. 2016). 
In mpMRI, traditional T1- and T2-imaging sequences are complemented 
with dynamic contrast enhancement and diffusion-weighted imaging (DWI), 
obtained at different diffusion values, i.e. b values. DW images are further 
processed to create apparent-diffusion coefficient (ADC) maps which reveal 
the tissue enhancement of suspicious foci. MRI thus offers good soft-tissue 
resolution without harmful radiation to the patient. Highly aggressive PC is 
densely packed with cells, which restricts the movement of water molecules at 
cellular level. This gives the tissue a distinct bright appearance on DWI. 
Conversely, low-grade cancer may resemble the surrounding benign tissue, 
making it more challenging to detect. ADC maps, derived from DWI, show 
malignant lesions as dark areas. As ADC is a mathematical parameter, it has a 
numeric value. Lower values have been shown to correlate with higher-grade 
cancer and, conversely, higher values with more benign tissue (Woodfield et 
al. 2010). This information can even serve, in highly specialized PC-MRI 
centers, to estimate possible Gleason grades of visualized tumors, but thus far 
no generally accepted cut-off values allow differentiation between tumor 
grades in ADC maps (deSouza et al. 2008, Kim et al. 2016, Shaish et al. 2017, 
Tamada et al. 2017, Wu et al. 2017). 
The popularity of prostate MRI can be explained by its ability especially to 
detect clinically significant PC. A 2015 review of 12 studies reported a fairly 
large range in the positive and negative predictive values (PPV and NPV) of 
mpMRI for this purpose: 34-93% and 63-98% (Fütterer et al. 2015). A more 
extensive and recent review appearing in 2017 covered 48 studies, including a 
meta-analysis of 8; it reported a median NPV of 88.1% for clinically significant 
PC at a prevalence of 30%, although when prevalence rose to 60%, NPV 
decreased to 67% (Moldovan et al. 2017). A recent prospective study found 
MRI to have a PPV of 65% for detection of any Gleason score 3+4 PC, at a 
prevalence of 53%, and an NPV of 76% (Ahmed et al. 2017). In sum, the NPV 
of MRI is consistently higher than the PPV, making MRI a good potential tool 
for ruling out clinically significant disease. 
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2.3.3.2 MRI-targeted biopsy 
Due to MRI’s ability to locate suspicious areas in the prostate, and its higher 
sensitivity in detecting high-grade versus low-grade cancers (Delongchamps 
et al. 2013, Pokorny et al. 2014, Schoots et al. 2015b, Siddiqui et al. 2016), 
MRI-guided biopsies are becoming exceedingly popular. MRI guidance or -
targeting refers to the practice of using MRI-provided information as to the 
location of a suspicious area, in order subsequently to target that specific area. 
MRI guidance can be implemented in the biopsy procedure in three ways: 1) 
directly by the urologist by what is called cognitive fusion, 2) by performing 
the biopsy procedure with simultaneous MR imaging, an “in-bore” procedure, 
or 3) by specific software that fuses the information from the MRI with real-
time US imaging. MRI targeting generally entails taking fewer biopsies than 
in the 12-core standard procedure. This is expected to reduce biopsy-related 
adverse effects, although evidence to support this is as yet limited (Overduin 
et al. 2013, Egbers et al. 2014). 
Prostate MRI can aid in decision-making in the case of negative prostate 
biopsies but persistant suspicion of PC. Performing MRI in this setting would 
possibly reveal tumors missed by random biopsies, often anteriorly located 
tumors, and aid in targeting in subsequent biopsy settings. A negative MRI 
could also help in the decision not to proceed to repeat biopsies (Hansen et al. 
2016, Thompson et al. 2016, De Visschere et al. 2016). Cancer-detection rates 
have been 22-52% as a result of MRI-targeted biopsies in this setting (Sonn et 
al. 2014, Mendhiratta et al. 2015, Salami et al. 2015). The National 
Comprehensive Cancer Network (NCCN) and EAU both recommend in their 
clinical guidelines considering mpMRI in men with previously negative 
biopsies and persistent suspicion of PC (Mohler et al. 2016, Mottet et al. 2017). 
2.3.3.3 Prebiopsy MRI 
One promising approach to improving diagnostic accuracy is to precede 
prostate biopsies with first-line MR imaging, in which the decision to advance 
to prostate biopsies is based on MRI results. If no tumors are visible, then 
biopsies may be unnecessary, but if a suspicious lesion is evident, then the 
biopsy procedure may, if desired, be performed with MRI guidance. Recent 
reports from prospective studies find that MRI, used as a triage test before the 
first prostate biopsy, can reduce unnecessary biopsies by 24-27% (Ahmed et 
al. 2017, Jambor et al. 2017). A prebiopsy MRI, followed by targeted biopsies, 
was also performed as a substudy of the Göteborg Randomised Screening 
Trial, with promising results (Grenabo Bergdahl et al. 2016). This has 
prompted a new prospective trial, the Göteborg-2, which will explore the role 
of MRI in screening for PC. Preceding the biopsies with MRI–outside of study 
settings–is currently rare in clinical practice, but is slowly becoming more 
common. For now, this practice is restricted by the additional costs and limited 
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availability of both MRI and radiological expertise in interpreting prostate 
MRI outside of PC-referral centers. 
There exist, however, some studies suggesting a limited benefit from this 
approach specifically in cohorts of men with no prior biopsies (Siddiqui et al. 
2015, Baco et al. 2016, Tonttila et al. 2016), in which cancer detection rates 
between targeted biopsies and systematic random biopsies were comparable. 
This is presumably because the prevalence of previously undetected cancers in 
this population is higher than in previously biopsied men. This is also 
highlighted by the lower median NPV of MRI and higher prevalence of PC in 
patients with no previous biopsies—69.9% with a prevalence of 51.4%—versus 
an NPV of 82.6% with a PC prevalence of 42% for men who have previously 
had a negative biopsy (Moldovan et al. 2017). These findings, considered 
together, suggest that performing MRI when suspecting PC may be more 
beneficial only after the first round of negative random biopsies, as the EAU 
and NCCN guidelines on PC currently recommend (Mohler et al. 2016, Mottet 
et al. 2017). 
Implementing prebiopsy MRI in the diagnostic pathway of PC seems, 
however, promising, with several trials underway and many reports sure to be 
forthcoming in the following years. Reports increasingly suggest it also to be a 
cost-effective strategy (de Rooij et al. 2014, Cerantola et al. 2016, Pahwa et al. 
2017, Venderink et al. 2017). 
2.4 PROSTATE CANCER TREATMENT 
2.4.1 STAGING AND RISK STRATIFICATION 
PC staging is based on the Tumour Node Metastasis (TNM) Classification 





Figure 7 The American Joint Committee on Cancer Tumour Node Metastasis criteria for 
prostate cancer. Reprinted by permission from John Wiley and Sons: CA: Cancer Journal for 
Clinicians, Feb 21, 2017, Buyyounouski et al., “Prostate cancer – major changes in the 
American Joint Committee on Cancer eight edition cancer staging manual”.  
Table 1. Staging of prostate cancer based on Tumour (T) Node (N) Metastasis (M) 
classification (Data from Brierley et al. 2016). 
Stage I T1-T2a N0 M0 
Stage II T2b-T2c N0 M0 
Stage III T3-T4 N0 M0 
Stage IV Any T N1 M0 
 
Any T Any N M1 
 
PC is a very heterogenous disease with great variation in its clinical course 
between the opposite ends of the disease spectrum (Lu-Yao et al. 2009, Rider 
et al. 2013). To better characterize PC and to guide the treatment planning, PC 
is divided into differing risk groups. Several risk stratifications have been 
created, but the most commonly used–the D’Amico classification–hails from 
1998 (D'Amico et al. 1998). It has since been validated in prospective cohorts 
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and serves, essentially unchanged, as a basis for contemporary risk group 
classifications (Mohler et al. 2016, Mottet et al. 2017) (Table 2). 
Table 2.  Risk stratifications in prostate cancer (Data from D’Amico et al. 1998, Mohler et 
al. 2016, and Mottet et al. 2017) 
Risk group D’Amico Classification 
(1998) 
NCCN Clinical Practice 
Guidelines in Oncology 
(2016) 
EAU Clinical Guidelines 
(2017) 
Very low  cT1, N0, M0 and  
  GS ≤ 6 and  
  PSA < 10 ng/ml and  
  cancer in < 3 biopsy cores 
and 
 
  ≤ 50% cancer in any biopsy 
core and 
 
  PSA-density < 0.15 ng/ml/g  
Low cT1-T2a, N0, M0 and cT1-T2a, N0, M0 and cT1-T2a, N0, M0 and 
 GS ≤ 6 and 
PSA ≤ 10 ng/ml 
GS ≤ 6 and 
PSA < 10 ng/ml 
GS ≤ 6 or  
GG = 1 and 
   PSA < 10 ng/ml 
Intermediate cT2b or cT2b-T2c or cT2b or 
 GS=7 or 
PSA 10-20 ng/ml 
GS = 7 or 
PSA 10-20 ng/ml 
GS = 7 or 
GG 2 or 3 or 
   PSA 10-20 ng/ml 
High cT2c or higher or cT3a or cT2c or higher or 
 GS ≥ 8 or 
PSA > 20 ng/ml 
GS 8-10 or 
PSA > 20 ng/ml 
GS ≥ 8 or 
GG 4 or 5 or 
   PSA > 20 ng/ml 
Very high  cT3b-T4 or  
  GS 5+4, 5+5 or  
  > 4 biopsy cores with GS 
8-10 
 
NCCN=National Comprehensive Cancer Network, EAU=European Association of Urology, cT=clinical 
tumor stage, N=node, M=metastasis, GS=Gleason score, PSA=prostate-specific antigen, GG=grade 
group 
 
The risk groups reflect an individual patient’s probability of biochemical 
disease recurrence, meaning detectable and rising post-treatment PSA levels, 
after radical therapies for PC and, as such, can serve as a guide in choosing 
appropriately effective treatments. The available treatment options for PC also 
depend on disease stage (Table 1). 
Stages I-III, i.e. localized and locally advanced diseases without nodal or 
distant metastases, are generally treated actively. The appropriate treatment 
choice is based on the risk group, i.e. low, intermediate, or high (Table 2). 
2.4.2 ACTIVE SURVEILLANCE (AS) 
Recent decades have seen a shift towards PC’s being diagnosed at 
progressively earlier stages. Treating all asymptomatic early-stage cancers 
aggressively with radical therapies would constitute overtreatment, because 
only some cancers would ever progress to cause harm during an individual 
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patient’s lifetime. This overtreatment would also lead to excessive harm since 
curative cancer therapies inherently carry a risk for adverse side-effects. It is 
these two factors–potential overtreatment and unnecessary harmful effects–
that led to the introduction of AS in the 1990’s (Epstein et al. 1994), and its 
adoption as the primary treatment for low-risk PC (Cooperberg et al. 2011). 
Immediate curative treatment has also failed to offer overall or disease-
specific mortality benefits in low-risk PC (Wilt et al. 2012, Hamdy et al. 
2016).  
AS aims at surveillance without the chance of missing the window of 
curability. Eligibility criteria for AS differ slightly between guidelines, but are 
most often essentially the Epstein criteria for insignificant disease: PSA-
density of < 0.15 ng/ml/g, Gleason score ≤ 6 in biopsies, a maximum of 2 
biopsy cores involving cancer, and < 50% of any biopsy core involving cancer 
(Epstein et al. 1994). Patients must also be sufficiently young and fit to be 
eligible for possible curative treatment if their disease progresses. In an 
autopsy study by Zlotta and co-workers (2013), 320 prostates were evaluated 
from men aged 20-89 who died without any history of PC. A significant 
proportion of all of these men (35.6%) had malignant lesions in their prostates, 
and although the majority of these cancers were Gleason score 6 (55.6%), 
another 25.6% harbored Gleason score 7 disease. This finding supports the 
notion that some men with low-volume Gleason 3+4 PC might be candidates 
for AS. However, one must bear in mind that Gleason pattern 4 clearly 
indicates increased risk for progression, also in an AS setting (Dall'Era et al. 
2017). 
2.4.2.1 Monitoring during AS 
Patients on AS are carefully monitored, usually by a predetermined 
surveillance protocol. Serial PSA measurements are integral to all forms of PC 
treatments and monitoring, most crucially in AS. Whereas a rising PSA level 
is indicative of tumor growth, such a rise can also result from benign causes 
such as prostate enlargement and inflammation, making it a somewhat 
unreliable and unspecific PC-monitoring tool on its own. Other markers, ones 
based on PSA measurements, have been developed: free PSA, meaning the 
amount of noncomplexed PSA in the bloodstream (Lilja 1993); %fPSA, the 
percentage of total PSA levels amounting to free PSA (Catalona et al. 1995); 
PSA density, the ratio of PSA level to estimated prostate volume (Benson et al. 
1992); and PSA and %fPSA kinetics, the rates at which PSA and %fPSA change 
in serial measurements (Carter et al. 1992). All these PSA-derived parameters 
have been utilized in the decision whether to continue AS or offer curative 
treatment, although with conflicting findings (Ross et al. 2010, Iremashvili et 
al. 2013, Vasarainen et al. 2015, Iremashvili et al. 2016). PSA-doubling time 
and PSA density are, however, still integral elements of the Prostate Cancer 
Research International Active Surveillance (PRIAS) protocol (Bokhorst et al. 
2016b). 
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 Repeat prostate biopsies are also an integral part of AS regimens. Some AS 
programs mandate immediate confirmatory biopsies to ensure the diagnosis 
of low-grade and low-volume disease before initiation of AS, whereas many 
require repeat biopsies after one year of AS. Thereafter, biopsies are generally 
repeated at predetermined time-points, usually at 2- to 4-year intervals. The 
findings of repeat biopsies guide the decision to either continue with AS or 
progress to definitive treatment. All AS protocols have specified criteria on 
what findings should trigger curative treatment (Bruinsma et al. 2016). 
Compared to PSA measurements, DRE, and prostate MRI, biopsies are 
invasive procedures, and as such, are uncomfortable. If patients refuse to take 
part in recommended repeat biopsies, the patency and safety of AS may be 
compromised (Bokhorst et al. 2015, 2016a), unless the lack of histological 
confirmation is compensated for by other means of follow-up, for example by 
prostate MRI or biomarkers. 
Some patients become anxious over knowing that they are living with a 
malignant disease and opt for immediate radical treatment, either RP or RT, 
even in the absence of signs of progression. Many patients, however, manage 
to continue AS for many years without its markedly affecting their quality of 
life (Vasarainen et al. 2012, Pham et al. 2016, Venderbos et al. 2017). 
2.4.2.2 Prospective AS studies 
AS is extensively studied in several high-volume cancer centers (Adamy et al. 
2011, Bul et al. 2013, Selvadurai et al. 2013, Klotz et al. 2015, Tosoian et al. 
2015, Welty et al. 2015, Godtman et al. 2016). One multi-center prospective 
study is the PRIAS trial, launched in 2006 at the Erasmus University Medical 
Center in Rotterdam, Netherlands (van den Bergh et al. 2007). It has evolved 
into the largest prospective AS trial, with over 150 participating centers from 
18 countries (Bokhorst et al. 2016b). The latter study was initially launched at 
eight centers, one of which being Helsinki University Hospital, which is the 
second largest participating center to date. Figure 8 presents the follow-up 





Figure 8 Outline of the follow-up in the Prostate Cancer Research International Active 
Surveillance study. PSA=prostate-specific antigen, PSA-DT=PSA-doubling tiome, 
PCa=prostate cancer. Figure reprinted by permission from Elsevier: European Urology, 2015 
Nov;68(5):814-21, Bokhorst et al., “Compliance Rates with the Prostate Cancer Research 
International Active Surveillance (PRIAS) Protocol and Disease Reclassification in 
Noncompliers”. 
2.4.3 CURATIVE THERAPIES 
2.4.3.1 Radical prostatectomy (RP) 
RP is a first-line treatment option in intermediate- or high-risk localized PC 
(Bill-Axelson et al. 2014). RP entails the surgical removal of the entire prostate 
gland and seminal vesicles. This procedure can be complemented with a 
lymphadenectomy when more accurate staging is deemed necessary or when 
a suspicion exists of lymph node involvement (Gandaglia et al. 2017, Nguyen 
et al. 2017). The operation can be performed either as a conventional open 
procedure or laparoscopically, with or without 3D technique or robot 
assistance. RP requires the patient to be sufficiently fit for general anesthesia 
and major surgery. In high-risk disease, RP with lymphadenectomy is the first-
line choice, but the more aggressive the disease, the more likely it is that RP 
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needs later to be complemented with adjuvant radiotherapy, leading to a so-
called multimodal treatment approach (Daly et al. 2011, Mottet et al. 2017). 
Reported rates of biochemical disease recurrence after RP range from 20 to 
50% (Novara et al. 2012, Meurs et al. 2013, Lee et al. 2015). 
In intermediate- and high-risk PC, RP is beneficial in that it reduces 
disease-specific mortality and development of metastases (Wilt et al. 2012, 
Bill-Axelson et al. 2014), even offering overall-survival benefit (Bill-Axelson et 
al. 2014) compared to no intervention. These reductions have been 
demonstrated in two large prospective trials where patients with localized, 
clinically T1-T2, disease were randomized to either RP or to observation: the 
Scandinavian Prostate Cancer Group (SPCG)-4 trial (Bill-Axelson 2014) and 
the Prostate Cancer Intervention versus Observation Trial (PIVOT) (Wilt et al. 
2012).  
The SPCG-4 trial recruited patients between 1989 and 1999 in Sweden, 
Finland, and Iceland. During its recruitment period, in Nordic countries, PSA 
testing was less prevalent than it is today. A large proportion of patients were 
therefore diagnosed with PC on clinical grounds, with 40% of patients being 
diagnosed with symptomatic disease. The SPCG-4 study revealed RP as 
offering significant reductions—compared to those from solely observation—
in overall mortality, disease-specific mortality, and development of metastases 
when all patients were pooled. This included an especially pronounced benefit 
for patients under 65 and for those with intermediate-risk disease (Bill-
Axelson et al. 2014).  
Findings from the PIVOT were more modest (Wilt et al. 2012). The patient 
cohorts in PIVOT and SPCG-4 were similar in many respects: PSA levels were 
< 10 ng/ml for 65% vs. 50% of patients, and biopsy Gleason scores were ≤ 6 
for 70% vs. 60%. The PIVOT patients were, however, recruited in the USA 
between 1994 and 2002, after PSA testing had become common and after the 
peak years of PC diagnoses in the USA. Of these patients, 50% had non-
palpable disease at diagnosis, compared to only 12% of SPCG-4 patients. This 
demonstrates how patients in the PSA era are diagnosed with PC at an earlier 
stage than before PSA testing, exemplifying lead-time bias. The PIVOT trial 
detected the potential benefit of RP versus observation only in subgroups of 
patients with PSA > 10 ng/ml and intermediate- to high-risk disease based on 
a post-hoc analysis (Wilt et al. 2012). 
More recently, the Prostate Testing for Cancer and Treatment (ProtecT) 
trial from the UK—a trial comparing AS, RP, and RT for screen-detected 
localized PC—demonstrated no survival benefit from radical therapies 
compared to that of AS (Hamdy et al. 2016). Development of metastases was, 
however, rarer for patients receiving radical therapies; RP and RT, than for 
those on AS. This highlights the importance of proper patient selection for 
radical therapies: considering that these patients were aged 50-69 at 
recruitment, this reduction in disease progression will, during prolonged 
follow-up, likely translate into improved survival.  
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2.4.3.2 Predicting outcomes after RP  
Assessing the long-term outcomes of RP objectively can be difficult because of 
variations between studies in reporting their results. Outcomes most often 
reported are biochemical recurrence, disease-specific mortality, or overall 
mortality, or, conversely, survival without these events. Need for secondary 
therapies, or disease progression or metastases after RP are also possible study 
endpoints. Depending on the endpoint of interest, outcomes also vary greatly 
between patient subgroups, with some groups reporting on said clinical 
outcomes for only low-risk or high-risk PC, for patients younger or older than 
65, for different clinical or pathological disease stages, or for such variables as 
positive or negative surgical margins. Obtaining tangible estimates of the 
results of RP for general patient populations is therefore challenging. 
Currently, patients are stratified into risk groups by their TNM stage, PSA, 
and Gleason scores (Table 2). Although intended for estimating the risk for 
disease recurrence after radical therapies, this risk stratification falls short. 
This holds especially true for the former Gleason-score 7 population, where 
patients’ outcomes have varied markedly. The new grade group system aims 
to improve risk stratification especially for this population (Epstein et al. 
2016a). The predictive performance of the new grade groups lacks validation 
from prospective contemporary cohorts but has been validated in 
retrospective studies (Epstein et al. 2016b, Spratt et al. 2016). The new grade 
grouping demonstrated, among other findings, marked differences in 
biochemical-recurrence-free survival rates between Gleason score 3+4 and 
4+3 cancers, especially after RP, differences evident with stratifications made 
from both pre-RP biopsies and RP specimens (Epstein et al. 2016b) (Figure 9). 
This five-tier stratification correlated with cancer-specific mortality, not just 
with biochemical recurrence, in contemporary SEER registry data from 2006-
2012 (He et al. 2017). The new grade grouping–however promising–is only 
part of the solution, as many parameters other than biopsy Gleason scores 
must be considered prior to decisions on appropriate treatment. 




Figure 9 Probability of survival without biochemical disease recurrence in the years following 
radical prostatectomy (RP), stratified by Grade groups (GG) from pre-RP biopsies. Green: 
Gleason score (GS) ≤6/GG1. Orange: GS 3+4/GG 2. Blue: GS 4+3/GG 3. Red: GS 8/GG 4. 
Purple: GS ≥9/GG 5. Figure reprinted by permission from Elsevier: European Urology, 2016 
Mar;69(3):428-35, Epstein et al., “A Contemporary Prostate Cancer Grading System: A 
Validated Alternative to the Gleason Score”. 
Several nomograms and risk-assesment tools for predicting the clinical 
outcome of PC patients after radical therapies have emerged. A literature 
search in 2008 discovered over 100 prediction tools (Shariat et al. 2008), and 
many more have since been developed. Some tools are designed for the pre-
treatment setting (Kattan et al. 1998, D'Amico et al. 1999, Cooperberg et al. 
2005, Stephenson et al. 2006), and some are intended for estimating 
outcomes after radical therapies (D'Amico et al. 1998, Moul et al. 2001, 
Roberts et al. 2001, Stephenson et al. 2005, Schroeck et al. 2008, Cooperberg, 
Hilton & Carroll 2011). Nomograms have also been designed for use upon the 
event of any biochemical recurrence after radical therapies (Abdollah et al. 
2013, Brockman et al. 2015, Dell'Oglio et al. 2016). For nomograms to be of 
definitive value in the clinical setting requires their being externally validated 
in the separate patient cohorts from which they were developed, with 
sufficiently long follow-up, to accurately predict meaningful clinical end-
points such as PC mortality. They also must be easy to use and interpret 
(Nguyen et al. 2009, Lughezzani et al. 2010, Teeter et al. 2013, Boehm et al. 
2016, Jaderling et al. 2016).  
For the postoperative prediction of PC-specific mortality, the CAPRA-S 
nomogram (Cooperberg, Hilton & Carroll 2011) appears to be the most robust, 
with its prognostic performance having been externally validated in several RP 
cohorts on several continents (Seong et al. 2013, Punnen et al. 2014, Seo et al. 
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2014, Tilki et al. 2015) and even in one radiation-therapy cohort 
(Zimmermann et al. 2016). Recently, MRI-derived parameters have been 
added to existing nomograms in an attempt to increase their predictive power 
(Morlacco et al. 2017, Zhang et al. 2017). 
2.4.3.3 Radiation therapy (RT)  
RT, also a treatment option with curative intent for intermediate- or high-risk 
PC, entails radiating the entire prostate gland, effectively killing the cancer but 
leaving the prostate in situ. RT is the preferred treatment in intermediate- or 
high-risk clinically T3 PC, because no data exist from randomized phase III 
trials for surgery in T3 disease, whereas several trials for RT, when 
supplemented with hormonal therapy, have been published in this setting 
(Widmark et al. 2009, Mottet et al. 2012). Analysis of data provided by the 
Surveillance, Epidemiology, and End Results (SEER) registry—a cancer 
registry of the National Cancer Institute in the USA, which covers 
approximately 28% of the US population—revealed that for 42 403 men 
diagnosed with localized PC in 2010, the proportion receiving RT as a form of 
local treatment rose along with ascending NCCN risk group. Of men with high-
risk disease, 43% were treated with RT and 31% with RP, and the 
corresponding figures were 38% and 45% for men with intermediate-risk 
disease (Mahmood et al. 2014). A study from 2015, looking at 13 803 men who 
received either RP, RT, or brachytherapy at two American institutes, 1995-
2008, also observed that men receiving RT had more adverse disease 
characteristics, such as higher PSA, higher-grade cancers, and more advanced 
clinical stage than did those receiving RP (Lee et al. 2015). 
RT can be performed either as external-beam radiotherapy, with daily 
administration spanning several weeks, or as high-dose-rate brachytherapy 
delivered directly into the prostatic tissue generally in one to four sessions. 
Low-dose-rate brachytherapy—also a form of RT—is recommended mainly for 
“low- and favorable intermediate-risk PC” (Mottet et al. 2017), where radical 
therapies are generally not encouraged. Low-dose-rate brachytherapy is 
therefore not commonly practiced.  
External-beam radiotherapy and high-dose-rate brachytherapy both 
customarily require neoadjuvant hormonal therapy in the 3 to 6 preceding 
months. In the case of high-risk PC the hormonal therapy is typically 
continued for 2 to 3 years post-treatment, to lower risk for disease recurrence 
(Bolla et al. 2009, 2010, Mottet et al. 2012). Biochemical-disease-recurrence 
rates after RT have generally been reported to be 20-30% (Kupelian et al. 
2002, Lee et al. 2015). 
A 2016 meta-analysis of 19 observational studies comparing RT and RP for 
treating localized PC found RT to associate with an increased risk of overall 
and PC-specific mortality (Wallis et al. 2016). This should, however, be 
interpreted with consideration for potential bias arising from: 1) residual 
confounding, which stems from RT’s being, compared to RP, more often 
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offered to older patients with more co-morbidities, and 2) different rates of 
salvage therapies, because RP is often followed by RT after disease recurrence, 
whereas if PC recurs after RT, surgery is seldom performed. The long-awaited 
10-year results of the ProtecT trial revealed no survival differences when 
patients were randomized to receive either RT or RP (Hamdy et al. 2016). 
2.4.4 OTHER THERAPIES 
2.4.4.1 Focal therapies 
The increasing detection of PC cases around the world, more often at earlier 
stages, has given rise to a novel treatment form, focal therapy (FT). FT entails 
treating only the malignant lesion in the prostate while leaving the rest of the 
gland intact. This approach aims to confer less treatment-related harm than 
do whole-gland therapies while providing acceptable cancer control. The 
energy that destroys the cancer can be delivered into the prostate focally by a 
wide selection of techniques: high-intensity focused ultrasound, 
radiofrequency ablation, and cryotherapy, among others. The targeting of the 
tumor is most often carried out with MRI. FT is advertised as a middle-ground 
therapy in situations in whiche AS might be deemed an unsafe option and 
whole-gland radical therapies would be too aggressive. FT is already being 
carried out in prospective clinical trials with promising preliminary results 
(Ahmed et al. 2015, Feijoo et al. 2016), but long-term safety and disease-
control results can be properly evaluated only after many years. FT also lacks 
any comparison with other curative therapies, namely RP and RT, most likely 
because these treatment forms are intended for distinctly different patients.  
2.4.4.2 Therapies for metastatic prostate cancer 
In disseminated stage IV disease, or if the patient is elderly or unfit or both, 
radical therapies such as RP and RT may be inappropriate. For an 
asymptomatic elderly or unfit patient, generally with less than 10-15 years’ life-
expectancy, one who hasn’t developed distant metastases, one treatment 
option is watchful waiting. This treatment option is not strictly outlined 
(Mottet et al. 2017), but can entail repeated PSA measurements and clinical 
check-ups to assess disease stage and general well-being. Interventions may 
become necessary when the patient develops symptoms, such as pain from 
skeletal metastases or LUTS.  
In metastatic PC, the primary treatment option is castration therapy 
because, until near the patient’s death, PC cells generally maintain their 
dependency on circulating testosterone. This dependency was discovered in 
1941 by two doctors, Huggins and Hodges, leading to Huggins’s later receiving 
the Nobel prize in medicine in 1966. Castration can be achieved either 
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surgically or by continuous administration of luteinizing hormone-releasing 
hormone (LHRH) agonists or antagonists. It can be complemented with early 
chemotherapy in select patients (Sweeney et al. 2015, James et al. 2016).  
Such hormonal therapy has, however, a limited effective period of 2-3 years 
before the disease eventually progresses, despite castration levels of 
testosterone, i.e. it becomes castration-resistant (Pienta et al. 2006). At this 
point, the next treatment option has conventionally been to advance to 
cytotoxic chemotherapy, mainly docetaxel, but recent years have seen the 
advance of an abundance of novel therapies for castration-resistant PC. These 
include a novel antiandrogen, enzalutamide (Scher et al. 2012), an androgen-
synthesis inhibitor, abiraterone (de Bono et al. 2011), an alpha-emitting 
radiopharmaceutical, radium-223 (Parker et al. 2013), and a novel cytotoxic 
drug, cabazitaxel (de Bono et al. 2010). Sipuleucel-T is the first FDA-approved 
immunological therapy for PC, although it is unavailable in Europe. Other 
immunological therapies are in development, but none have thus far 
demonstrated overall-survival benefit in phase III trials (Slovin 2016). 
Optimal patient selection, timing, and treatment sequences of these novel 
therapies are thus far unknown, but are the focus of intense research (Sweeney 
et al. 2015, James et al. 2016, Ritch et al. 2016). 
2.5 INFECTIOUS COMPLICATIONS OF PROSTATE 
BIOPSIES 
2.5.1 BIOPSY-RELATED COMPLICATIONS 
Transrectal biopsies can cause many complications for patients (Borghesi et 
al. 2017), among which are pain, hematuria, hematospermia, rectal bleeding, 
and infection. Prostate biopsy may also cause temporary impairment to 
erectile function, which usually returns to baseline by 1-6 months after the 
procedure (Borghesi et al. 2017). Non-infectious complications are most often 
mild and self-limiting, only rarely requiring hospitalization (Borghesi et al. 
2017), whereas infectious complications can be more severe.  
During the biopsy procedure, the needles pass through the rectal wall 
repeatedly. Although the procedure occurs in conjunction with antibiotic 
prophylaxis, it is nearly impossible to completely avoid all infections when 
operating in a region contaminated with fecal bacteria. Transrectal biopsies 
therefore inherently carry a risk for infectious complications, occurring in up 
to 7% of procedures (Eichler et al. 2006). These complications range in 
severity from the mildest forms’ being asymptomatic bacteriuria or 
symptomatic lower urinary tract infections to more severe forms including 
febrile urinary tract infections, with their reported incidence of 2.2-4.2% (Loeb 
et al. 2012, Batura et al. 2013), and in the worst cases, septic infections, the 
incidence of which ranges from 0.6 to 3.1% (Carmignani et al. 2012, Hayatzaki 
et al. 2014, Bruyere et al. 2015, Bulut et al. 2015, Liss et al. 2015b). The latter 
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manifestations are the most feared, since they may lead to patients’ requiring 
intensive care, can cause abscesses and other secondary complications, and 
may even prove fatal. Mortality rates at 30 days have been reported at 0.09-
0.3% (Loeb et al. 2011, Nam et al. 2013), but the rates increase with longer 
observation periods, with a 90-day-mortality rate of 1% reported from Sweden 
(Lundström et al. 2014) and a 120-day-rate of 1.3% from Canada (Gallina et al. 
2008). Mortality is associated with septic complications, advanced age, and 
worsening of co-morbid conditions. 
2.5.2 FLUOROQUINOLONE RESISTANCE  
The last 15-20 years have seen an alarming rise in the incidence of post-biopsy 
infections (Nam et al. 2013, Anastasiadis et al. 2015). One explanatory factor 
is the number of biopsy procedures increasing as a result of widespread PSA 
testing, the aging populations in developed countries, and the emergence of 
AS as a treatment strategy for low-risk PC. Another contributory factor is the 
increasing resistance of enteric bacteria, typically Escherichia coli, to 
fluoroquinolone (FQ) antibiotics (Zowawi et al. 2015) (Figures 10 and 11).  
 
 
Figure 10 Increasing proportions of non-fluoroquinolone-susceptible Escherichia coli in 
European countries, from 2000 to 2015. Gray indicates no calculated data. (Source: 
European Centre for Disease Prevention and Control, website accessed 16 Feb 2017, 





Figure 11 Global prevalences of fluoroquinolone resistance in Gram negative uropathogens. 
Figures from studies published in 2009-2014. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Urology, 2015(12), 570–584, Zowawi et al., “The emerging 
threat of multidrug-resistant Gram-negative bacteria in urology”, copyright 2015. 
FQs are the prophylactic antibiotics most commonly used for the prostate 
biopsy procedure (Mottet et al. 2017), due to their easy oral administration, 
generally good coverage against enteric bacteria, and favorable drug 
penetration of prostatic tissue (Dan et al. 1986). The cause of biopsy-related 
infections is therefore often  FQ-resistant bacteria residing in the patients’ 
rectal flora which are translocated by the penetrating biopsy needles 
(Carmignani et al. 2012, Williamson et al. 2012, Taylor et al. 2013, Ehdaie et 
al. 2014, Hayatzaki et al. 2014, Rudzinski et al. 2014, Song et al. 2014, Liss et 
al. 2015a, 2015b, Marino et al. 2015). 
Rising global levels of FQ resistance result from the liberal administration 
of FQs to treat community-acquired urinary tract infections (Fasugba et al. 
2015), from the use of antibiotics in agriculture in developed countries (Oliver 
et al. 2011), and from easy over-the-counter access to antibiotics in developing 
countries. 
     A risk factor clearly associated with developing post-biopsy infections is 
recent international travel (Patel et al. 2012, Anderson et al. 2015). The 
mechanism underlying this association is temporary colonization of the 
patient’s intestinal flora by FQ-resistant bacteria (Kantele et al. 2014) picked 
up when traveling to an area that exhibits marked FQ resistance. The recent 
use of antibiotics–FQs or some other–may also raise the risk for post-biopsy 
infections (Patel et al. 2012, AbuGhosh et al. 2013, Loeb et al. 2013, Anderson 
et al. 2015, Bruyere et al. 2015). Speculation is that the mechanism is 
antibiotics’ temporary disturbance of the balance in rectal bacterial flora, 
again allowing for temporary colonization by more virulent, often FQ-resistant 
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strains. Many studies have demonstrated FQ-resistant bacteria in the rectal 
flora to be a strong risk factor for development of post-biopsy infections. This 
has prompted the introduction of prebiopsy rectal swabs that allow the 
tailoring of antibiotic prophylaxis instead of administration of possibly 
ineffective FQs. This strategy has been effective in reducing post-biopsy 
infections (Duplessis et al. 2012, Taylor et al. 2012, Suwantarat et al. 2013, 
Roberts et al. 2014, Li et al. 2016), and it is suggested to be cost-effective 
(Duplessis et al. 2012, Taylor et al. 2012, Li et al. 2016). 
     Another strategy to reduce post-biopsy infectious complications is to 
circumvent the contaminated transrectal route and perform transperineal 
biopsies instead. Sepsis rates have generally been lower following 
transperineal procedures, although such procedures are associated with 
higher rates of urinary retention (Bennett et al. 2016). This procedure, 
however, requires spinal anesthesia, making it more demanding than 
transrectal biopsy, which can be performed with local anesthesia as an out-
patient procedure.   
2.5.3 OTHER RISK FACTORS FOR POST-BIOPSY INFECTIONS 
Effort has gone into identifying other factors possibly raising the risk for 
post-biopsy infections. Some report an increased risk as being associated 
with repeated biopsies (Ehdaie et al. 2014). This is worrisome because repeat 
prostate biopsies are an integral part of the AS protocols (Bruinsma et al. 
2016), but patients who develop post-biopsy complications may be reluctant 
to comply with programed repeat biopsies (Bokhorst et al. 2015, 2016a). 
Having undergone prostate biopsies typically means having recently taken 
FQs as a prophylactic antibiotic. This predisposes the patient to harboring 
FQ-resistant bacteria, placing the patient more at risk for post-biopsy 
infection (Roberts et al. 2014). Currently no consensus exists as to whether 
repeat biopsies raise the risk for infections, although large-scale studies 
(Loeb et al. 2013a, Aly et al. 2015, Bokhorst et al. 2016a, Halpern et al. 2017) 
and one meta-analysis (Roberts et al. 2014) suggest no connection.  
Any factors weakening a host’s ability to fight bacterial infection can 
naturally be considered risky. Regarding biopsy-related infections, these 
factors may include diabetes (Simsir et al. 2010, Loeb et al. 2012, Halpern et 
al. 2017), other comorbidities (Aly et al. 2015, Anastasiadis et al. 2015, Shahait 
et al. 2016), old age (Anastasiadis et al. 2015, Shahait et al. 2016), and urinary-
catheter use (Simsir et al. 2010, Eruz et al. 2017). 
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2.6 MRI IN THE AS OF PROSTATE CANCER 
2.6.1 MRI IN SELECTING PATIENTS FOR AS 
No clinical guidelines on AS currently recommend the routine use of MRI 
(Bruinsma et al. 2016). It is, however, increasingly employed, and several AS 
guidelines recommend it in situations when any discrepancy emerges between 
biopsy findings and clinical parameters, such as PSA levels or DRE or 
transrectal ultrasound findings. The two most common indications to perform 
prostate MRI for low-risk-PC patients are: 1) to confirm the diagnosis of low-
grade, low-volume disease and to determine whether no significant lesion may 
have been missed by random biopsies, and 2) to monitor disease progression 
during AS (Schoots et al. 2015a). 
Roughly one-third of men on AS will have their disease reclassified as 
worsening in their first confirmatory or follow-up biopsies (Dall'Era et al. 
2012) and will therefore no longer be eligible for AS. This largely fails to reflect 
the true clinical progression of their disease, but rather reflects undersampling 
in their diagnostic biopsies. This inaccuracy has prompted the use of prostate 
MRI with the goal of better identifying those men for whom AS is the proper 
treatment option. In their 2015 review, Schoots and-co-workers (2015a) 
concluded that prostate MRI in men eligible for AS, if based on biopsy data, 
reveals a positive lesion in 70%. When these men receive repeat biopsies, with 
or without MRI targeting, 47% will be reclassified as having worse disease than 
at inclusion for AS. In short, this would imply that if MRI were routinely 
performed for all men before initiation of AS, one-third would evidently have 
a poorer prognosis than predicted and would no longer be suitable candidates 
for AS.  
There exist, however, caveats in interpretation of these results. First, 
studies reporting on reclassification rates of MRI-positive men cannot always 
report on corresponding rates for those men without an MRI-positive lesion, 
because such men will not necessarily undergo repeat biopsies. Second, when 
performing repeat biopsies with MRI targeting, the cancer yield tends to be 
higher than for random biopsies, leading automatically to higher 
reclassification rates. The PRIAS protocol was accordingly modified in 2015 so 
that if the diagnostic biopsies were performed with MRI guidance, the protocol 
would allow a higher number of positive cores at inclusion. Consequently, the 
number of positive cores permitted during repeat biopsies was adapted based 
on the number at baseline (Bokhorst et al. 2016b). Despite these caveats, 
prostate MRI shows promise as a tool for better risk stratification at AS 
inclusion. 
2.6.2 MRI AS A FOLLOW-UP TOOL IN AS  
Another indication for prostate MRI during AS is to monitor possible disease 
progression. Since AS is a treatment option reserved solely for low-volume, 
Review of the literature 
44 
low-grade PC, employing MRI as a follow-up tool for AS patients is somewhat 
challenging (Schoots et al. 2015a). Low-grade PC is hard to differentiate from 
benign tissue, making tumor monitoring difficult. The goal of MRI in AS is to 
detect those lesions prompting active therapies, i.e. clinically significant 
disease. MRI is well suited to this purpose because of its NPV for Gleason 4 or 
higher grades (Moldovan et al. 2017). 
Before adopting MRI into AS protocols, what should, however, be decided, 
is what constitutes radiological progression and how MRI findings dictate 
further action. The Prostate Cancer Radiological Estimation of Change in 
Sequential Evaluation (PRECISE) panel of 19 experts in the fields of urology, 
radiology, and radiation oncology has recently released its recommendations 
for documenting changes in MRI findings during AS (Moore et al. 2017). Serial 
MRIs may monitor the size of tumors or, alternately, other radiologic 
parameters such as decrease in ADC values (van As et al. 2009, Morgan et al. 
2011) or other adverse features. Standardized structured reporting systems for 
MRI such as PI-RADS (Weinreb et al. 2016) are essential in properly 
comparing serial images, and ideally the same versions of the reporting 
systems should be the choice. Another issue is how great a change between 
images should trigger further action or whether absolute lower limits are 
necessary, such as a certain tumor diameter or a prespecified PI-RADS score 
(Moore et al. 2017). 
When performing MRI to monitor AS patients, it is natural to utilize MRI 
data to aid in guiding repeat biopsies. Performing MRI-guided biopsies in 
addition to standard biopsies during AS follow-up has allowed detection of 
more Gleason-grade upgrades than by standard biopsies alone (Hoeks et al. 
2014, Walton Diaz et al. 2015, Ma et al. 2017). This approach is, however, 
impractical, because the goal of MRI-guided biopsies is to achieve accurate 
results with fewer cores than standard biopsies require, instead of with more 
cores. The as-yet-limited added value of MRI-guided biopsies in the AS setting 
may be explained by the patient population: MRI-guided procedures perform 
best when targeting high-grade lesions, and AS patients by definition harbor 
only low-volume, low-grade PC. 
Since prostate biopsy is an invasive and often problematic procedure, one 
speculation is that in AS, prostate MRI could someday replace repeat biopsies. 
This would entail continuing surveillance as long as PSA and MRI findings 
remain stable, showing no disease progression, but otherwise advancing to 
active treatment. This may already be practiced in real-life, but accurate 
knowledge of the NPV of MRI still needs confirmation from biopsies 
performed on men with negative MRI findings. Thus far, the NPV for detecting 
Gleason score ≥ 7 PC after a negative MRI in AS patients is reported to be as 
high as 93.1-100% (Wysock et al. 2016, Lu et al. 2017). The PRIAS study group 
has launched an MRI sidestudy with the hopes of further clarifying this issue 
among others (Hoeks et al. 2014). For prostate MRI to trigger active therapies 
by itself would require a strict definition of radiological disease progression 
and firm knowledge of the correlation between adverse radiologic features and 
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with histopathological findings. MRI can result in false-positive results, so the 
decision to advance to active therapies is hardly ever made without 
histopathological confirmation from biopsy. Prostate MRI cannot as yet 
replace repeat biopsy in AS. 
2.7 BIOMARKERS IN PROSTATE CANCER  
2.7.1 MULTIPLE-GENE ASSAYS 
Novel tools for better prediction of patient outcomes are constantly appearing. 
Today, great emphasis is upon finding biomarkers that will aid in outlining a 
PC-patient’s outcome. Biomarkers can range from genes, gene products, or 
cancer-metabolism products to radiological findings that have, in some 
circumstances, been associated with either aggressive PC, risk for expansion, 
or the risk for developing metastases. The presence of such single or multiple 
biomarkers in a patient’s blood or urine sample, prostate biopsy, RP specimen, 
or MR image would theoretically indicate the patient’s having worse disease 
than the standard prediction tools would indicate.  
The first commercially available gene-expression application was the 
Prolaris® test introduced in 2010, which measures the expression of 46 genes 
found to correlate with PC cell proliferation, producing a cell-cycle progression 
score. This score, combined with the PSA and the Gleason score, aims to 
predict the 10-year risk for PC progression and risk of death. Other genetic 
panels have since entered the market, namely the Oncotype DX® that tests for 
17 genes, and the 22-gene Decipher® test. These commercial genetic panels 
are marketed as additional predictive tools to aid physicians and patients in 
making treatment decisions. Oncotype DX®, a prognostic tool also for breast 
cancer,  aids in deciding whether a patient with low-risk PC can safely choose 
AS instead of immediate radical therapy (Klein et al. 2014, Cullen et al. 2015), 
whereas Decipher® aims to help in deciding on possible adjuvant therapies 
after RP (Den et al. 2015, Klein et al. 2015). The Prolaris® test, according to its 
manufacturer, is suited for both scenarios (Freedland et al. 2013, Cuzick et al. 
2015, Koch et al. 2016).  
Being laboratory-developed tests, these commercial panels lack approval 
by the FDA (Office of Public Health Strategy and Analysis, Office of the 
Commissioner, Food and Drug Administration 2015), but are covered by some 
insurance policies and advocated in the USA by NCCN clinical guidelines on 
PC (Mohler et al. 2016). These tests have shown promising results in 
prospective validation studies, as reviewed by Boström and co-workers (2015), 
but are currently expensive, with their cost-effectiveness unestablished. There 
is, interestingly, also no overlap between genes for which these assays test. 
Performances of these panels have yet to be compared with each other in head-
to-head analyses (Moschini et al. 2016). 
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2.7.2 SINGLE BIOMARKERS, FISH, IHC, AND TMA  
Single biomarkers are most often single genes or gene products detectable in 
blood, urine, or tissue samples. One detection method is fluorescence in situ 
hybridization (FISH), which finds DNA sequences or RNA targets in cancer 
cells. FISH can be performed on fresh or formalin-fixed paraffin-embedded 
tissue samples, but requires fluorescence microscopy and is a somewhat 
cumbersome technique. An alternate easier and less-costly method is 
immunohistochemistry (IHC), which detects protein products of relevant 
genes in malignant tissues. Compared to RNA sequencing of multiple genes, 
the study of single biomarkers by IHC is easy and inexpensive. If desired, it 
can be implemented in diagnostic processes in clinical practice, for example in 
the histopathologic analysis of diagnostic biopsies or RP specimens.  
A method for analyzing samples from hundreds of patients is to construct 
a tissue microarray (TMA). TMAs are paraffin blocks that contain tissue 
sample cores from dozens of patients. These blocks are sectioned to produce 
thin (5-µm) sections for study by FISH or IHC techniques (Figure 12), allowing 
for rapid analyses of large patient series. As such, TMAs of large historic 






Figure 12 Immunohistochemical stainings of tissue microarray (TMA) cores with prostate 
cancer (PC). A. PC demonstrating cytoplasmic loss of PTEN expression (=pale gray 
cytoplasm). B. Sequential section of the same TMA spot as in A, but demonstrating positive 
nuclear ERG expression (=brown nuclei). C. Sequential section of same TMA spot as in A 
and B, but demonstrating high nuclear AR expression (=dark brown nuclei). D. A separate 
core demonstrating negative nuclear ERG expression (=gray nuclei). Modified from a figure 
published in Modern Pathology, 29(12):1565-74 (2016), Lahdensuo et al., ”Loss of PTEN 
expression in ERG-negative prostate cancer predicts secondary therapies and leads to 
shorter disease-specific survival time after radical prostatectomy” and reprinted here by 
permission from Macmillan Publishers Ltd. 
2.7.3 TMPRSS2:ERG FUSION 
An interesting and widely studied PC biomarker is the fusion of TMPRSS2, a 
serine protease gene, with ERG, an ETS family transcription factor oncogene. 
Among the functions of ERG and the other 27 members of the ETS family of 
transcription activators and repressors is regulation of gene expression in 
cancers of the breast, reproductive organs, and prostate (Gutierrez-Hartmann 
et al. 2007). TMPRSS2:ERG fusion is detectable in prostatic tissue by either 
FISH or IHC methods, of which the latter involves detecting the expression of 
the protein ERG. Such fusion is considered the most prevalent genetic 
alteration in PC development, present in 40-80% of PC samples (Tomlins et 
al. 2005, Yoshimoto et al. 2008, Hoogland et al. 2011, Minner et al. 2011, 
Pettersson et al. 2012, Attard et al. 2015). It is also evident in premalignant 
tissues, indicating this alteration to be an early occurrence in carcinogenesis. 
This fusion is therefore not unique to malignant tissues, but it is detectable in 
increasing numbers with rising degrees of disease aggressiveness and stage 
(Pettersson et al. 2012, Attard et al. 2015). This has been the premise for use 
of TMPRSS2:ERG fusion status to gauge an individual patient’s poorer 
prognosis. One hypothesis, however, is that TMPRSS2:ERG fusion is 
necessary in early PC development, but less functionally relevant in later 
disease stages (Baena et al. 2013). Positive ERG status has conversely also 
correlated in RP specimens with less aggressive histology (Kimura et al. 2012, 
Suh et al. 2012). This would explain why positive TMPRSS2:ERG fusion status 
appears to lack prognostic power in terms of mortality (Pettersson et al. 2012, 
Fleischmann et al. 2014). 
2.7.4 PTEN LOSS 
Another common genetic phenomenon is loss of function of the tumor 
suppressor gene PTEN, also detectable with either FISH or IHC techniques 
(Lotan et al. 2011, Picanco-Albuquerque et al. 2016). Original exploratory 
studies have detected, in PC samples, heterozygous PTEN loss in 29-55% 
(Cairns et al. 1997, Feilotter et al. 1998, Pesche et al. 1998) and homozygous 
PTEN loss in 10-15% (Cairns et al. 1997, Wang, Parsons & Ittmann 1998, 
Whang et al. 1998).  
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 PTEN loss activates the PI3K/Akt signaling pathway driving anabolic 
metabolism in cancer cells (Ward et al. 2012), which consequently activates 
the mTOR pathway, which promotes cell division (Hahn-Windgassen et al. 
2005). PTEN loss thus occurs in many cancers other than PC. Its prognostic 
value has been under study in breast cancer (Wang et al. 2013, Beg et al. 2015), 
colorectal cancer (Atreya et al. 2013, Lin et al. 2015), endometrial cancer 
(Westin et al. 2015), and ovarian cancer (Martins et al. 2014), among others, 
and it is associated with a worse prognosis in many other cancers (Qiu et al. 
2015). As a driver of disease progression, PTEN loss, however, seems to be of 
more importance in PC than in other cancer types, often correlating with more 
aggressive disease and, consequently, poorer outcomes, such as unfavorable 
findings at RP (Lotan et al. 2014, Guedes et al. 2016), biochemical-disease 
recurrence (Chaux et al. 2012, Krohn et al. 2012, Barnett et al. 2014, Lotan et 
al. 2016, Murphy et al. 2016), PC metastasis, and death (Lotan et al. 2011, 
Cuzick et al. 2013, Mithal et al. 2014, Ahearn et al. 2015). 
For a single prognostic biomarker to be of value in improving risk 
stratification of PC it would ideally be implemented at the diagnostic stage to 
aid in treatment planning. PTEN loss detected in pre-treatment biopsy 
specimens has predicted disease upgrading or non-organ confined disease at 
RP (Lotan et al. 2014, Guedes et al. 2016, Lokman et al. 2017), shorter time to 
biochemical recurrence after brachytherapy (Fontugne et al. 2014), and even 
increased PC mortality after RP (Mithal et al. 2014). Given the promising 
prognostic power of PTEN loss, determining PTEN expression status from 
diagnostic biopsies or RP specimens could probably aid in treatment planning. 
This may prove most beneficial for patients assumed to be at low risk who are 
deciding between either AS or radical therapies. 
2.7.5 TMPRSS2:ERG FUSION AND PTEN LOSS TOGETHER 
Since TMPRSS2:ERG fusion can be evident in benign tissue as well, the fusion 
alone fails to predict an aggressive disease course (Hoogland et al. 2011, 
Minner et al. 2011, Pettersson et al. 2012, Leinonen et al. 2013, Xu et al. 2014), 
but it may be an indicator of other cancer-promoting mechanisms at play. 
TMPRSS2:ERG fusion and loss of PTEN are often detected together (Attard et 
al. 2009, Carver et al. 2009, Han et al. 2009, Gumuskaya et al. 2013, Shah et 
al. 2015, Lotan et al. 2016), suggesting a causal link between the two genetic 
transformations, with PTEN loss assumed to be a later-occurring 
phenomenon (Krohn et al. 2014). Their joint occurrence has, in some studies, 
reflected an even worse clinical presentation than does either genetic 
transformation alone (Yoshimoto et al. 2008, Leinonen et al. 2013, Fontugne 
et al. 2014). The prognostic significance of PTEN loss is, however, probably so 
strong that it can predict a poorer outcome also in the absence of 
TMPRSS2:ERG fusion (Reid et al. 2010, Ahearn et al. 2015, Qu et al. 2016). 
     Interestingly, the commercially available genetic panels—Prolaris®, 
Oncotype DX®, and Decipher®–do not test for ERG fusions or loss of PTEN, 
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but instead for wholly different genes mostly associated with cell-cycle 
progression, cell profileration, and androgen signaling. This reflects the speed 
at which novel biomarkers associated with poorer PC prognosis are constantly 
being discovered.   
2.7.6 ASSOCIATIONS OF ERG AND PTEN WITH THE ANDROGEN-
RECEPTOR PATHWAY  
TMPRSS2 is an androgen-regulated gene, and TMPRSS2:ERG fusion is 
generally thought to occur in the presence of, and through the influence of 
circulating androgens such as testosterone (Tomlins et al. 2005). Until the 
castration-resistant stage, depriving PC of androgens halts its progress. The 
effects of androgens in PC cells are mediated via the androgen receptor (AR). 
Elevated levels of AR expression in PC appear to correlate with more 
aggressive disease (Donovan et al. 2010, Sahu et al. 2011, Qu et al. 2016). In 
the current era of rapid development of novel drugs aimed at treating PC in its 
castration-resistant stage, much interest focuses on elucidating the 
mechanisms by which castration-resistant PC progresses despite androgen 
deprivation (Hoang et al. 2017). 
The relationship between AR activity and TMPRSS2:ERG fusion apperars 
to be reciprocal (Hoogland et al. 2011, Minner et al. 2011, Huang et al. 2014b). 
One murine study has shown fusion of TMPRSS2 with ETS transcription 
factors–ERG and ETV1–to upregulate AR, even predisposing PC tissue to loss 
of PTEN function (Chen et al. 2013). Other groups, however, have found this 
to be true only for ETV1, and found that TMPRSS2 fusion with ERG may 
actually down-regulate AR (Shin et al. 2009, Yu et al. 2010, Baena et al. 2013), 
which may then promote loss of PTEN. This would suggest that high AR 
activity may be promoted by agents other than TMPRSS2 fusion with ERG, for 
example, by ETV1, IGF-1 (Culig et al. 1994), or FOXA1 (Sahu et al. 2011), 
among many others (Hoang et al. 2017). 
Complicating the issue further, loss of PTEN has also been found to 
downregulate AR, promoting androgen-independent progression of PC by 
activated compensatory signaling pathways (Kaarbo et al. 2010, Carver et al. 
2011, Mulholland et al. 2011). Findings are, however, conflicting, with one 
group reporting that the direction of this interaction is dependent on stage of 
PC. Loss of PTEN and consequent activation of the PI3K/Akt/mTOR pathway 
suppresses AR activity in androgen-dependent LNCaP cells, whereas 
conversely, this pathway enhances AR activity in LNCaP cells with high 
passage numbers (Lin et al. 2003, 2004). This finding suggests that high AR 
activity, when in the setting of PTEN loss, would reflect a more advanced 
disease stage. Figure 13 outlines some of the crosstalk between TMPRSS2 
fusions and other pathways. 
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Figure 13 A. Fusion of TMPRSS2 and ERG through chromosomal deletion and TMPRSS2 
with ETV1 by translocation. Figure reprinted by permission from Elsevier: European Urology 
Supplements, 2010 Dec;9(11):794-99, Martinez-Pineiro, “Personalised Patient Diagnosis and 
Prognosis in Prostate Cancer: What Are the Future Perspectives?” B. Consequent 
interactions with AR signaling and loss of PTEN (Illustration by Kristiina Tammisalo) 
These findings may have clinical significance regarding androgen-
deprivation therapy in advanced PC. A poorer response to androgen 
deprivation has been reported both for patients with a negative 
TMPRSS2:ERG fusion status (Attard et al. 2009, 2015, Graff et al. 2015) and 
for those with loss of PTEN (Ham et al. 2009, Mulholland et al. 2011, Mithal 
et al. 2014, Ferraldeschi et al. 2015). In sum, this would suggest that patients 
with negative TMPRSS2:ERG fusion status and loss of PTEN would represent 
a sub-population of PC patients with shorter survival after development of 
metastases. Results from preclinical studies suggest that patients with loss of 
PTEN and with activated PI3K/Akt/mTOR signaling may benefit from therapy 
involving androgen-deprivation coupled with PI3K/Akt/mTOR-targeting 
agents (Kaarbo et al. 2010, Carver et al. 2011, Mulholland et al. 2011, Yadav et 
al. 2016). This strategy has been tested in phase I-II trials with varying results 
(Meulenbeld et al. 2013, Chow et al. 2016), and several trials are currently 
ongoing (Statz et al. 2017).  
In conclusion, AR signaling with associated TMPRSS2:ERG fusions and 
the PI3K/Akt/mTOR pathway–two of the most important pathways in PC–
cooperate in the development of androgen-independent and eventually fatal 
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PC. Their interactions are, however, complex and need clarification from 
further research with contemporary patient cohorts. 
Aims of the study 
52 
3 AIMS OF THE STUDY 
The true clinical outcome for an individual patient diagnosed with PC is 
inaccurately predicted with currently available diagnostic tools. The need is 
ongoing for better strategies in the diagnosis and treatment-planning of PC. 
The aims of this thesis study were to evaluate safety for the patient and the 
performance of conventional prostate biopsies, the utility of MRI in the AS of 
PC, and the value of putative prognostic PC tissue biomarkers. 
 
The specific aims were to discover and establish: 
 
1) incidences and possible risk factors for bacteremic infectious 
complications following transrectal biopsies (Study I). 
2) ability of transrectal biopsies to estimate tumor size and location in RP 
specimens. Morphologies of significant and index tumors were also a 
subject of study (Study II). 
3) suitability of prostate MRI in the AS of PC (Study III). 
4) effects of TMPRSS2:ERG fusion and PTEN loss in clinical outcomes of 
surgically-treated PC (Study IV). 
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4 PATIENTS AND METHODS 
4.1 STUDY COHORTS AND TIMELINES 
Study I 
 
The laboratory archives of the entire Helsinki and Uusimaa Hospital District 
(HUSLAB Laboratory Services), covering a population of 1.62 million people, 
provided the study population. The study analyzed 17 183 biopsy procedures, 
performed at 11 urological centres, on 13 303 men during the period 1 January 
2005 to 31 December 2013. 
The annual incidence of post-biopsy bacteremias were determined by 
means of data searches in the centralized laboratory archives of the hospital 
district (HUSLAB), housing data both on all biopsies and all blood cultures. 
First, a list of all biopsy procedures was extracted with the procedure code for 
transrectal biopsies. A list of all positive blood cultures of male patients over 
age 20 during the same time period also came from the same records. Patients 
who had both undergone a biopsy procedure and had a positive blood culture 
were then detectable by matching with patients’ social security numbers. 
Blood cultures positive within 30 days of the biopsy we considered relevant. 
These men were confirmed by review of their medical records to have suffered 
a post-biopsy complication. Patients who had other causes of bacteremic 
infections were excluded from analysis, leaving 111 men as the bacteremic 
cohort. More detailed information regarding possible risk factors was available 




Study II was retrospectively conducted on 96 patients treated with RP between 
February 2009 and April 2010 at Helsinki University Hospital. These study 
patients were selected from among the first 162 patients treated with 
laparoscopic robot-assisted RP at our clinic who had had their diagnostic 
biopsies taken at our institution. The 96 study patients also had to have 
histological slides of RP specimens available for re-evaluation. Main 
presurgery characteristics and surgical findings are summarized in Table 3.  
Study II tested the performance of the standard 12-core transrectal biopsy 
in detecting tumors and predicting tumor location and size. Detection of 
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Table 3. Characteristics of the 96 patients in Study II. Modified from two tables published 
as ”Performance of transrectal prostate biopsies in detecting tumours and implications for 
focal therapy,” Lahdensuo et al., in the Scandinavian Journal of Urology,© Acta Chirurgica 
Scandinavica Society, reprinted by permission of Taylor & Francis Ltd, on behalf of the Acta 
Chirurgica Scandinavica Society. 
Median age, years (range) 61.7 (45-74) 
Median preoperative PSA, ng/ml (range) 7.2 (1.5-28.0) 
Preoperative PSA, ng/ml, n (%)  
     0-4.0 13 (13.5) 
     4.1-10.0 67 (69.8) 
     >10.0 16 (16.7) 
Biopsy Gleason score, n (%)  
     6 39 (40.6) 
     3+4 36 (37.5) 
     4+3 15 (15.6) 
     ≥8 6 (6.2) 
Median combined biopsy cancer percentage, % (range) 5.4 (0.5-100) 
Median combined biopsy cancer length, mm (range) 8.0 (0.5-97.0) 
Positive surgical margins at RP 26 (27.1) 
Extraprostatic extension at RP 16 (16.7) 
RP Gleason score, n (%)  
     6 15 (15.6) 
     3+4 55 (57.3) 
     4+3 17 (17.7) 




These purposes required re-evaluation of study patients’ archived RP 
slides. The prostates had been dissected in their entirety and mounted serially 
from apex to base to create the slides. During re-evaluation, tumor location, 
Gleason score, and size were recorded and charted by prostate sextant. The 
same sextant division was utilized as in prostate biopsy sampling, making 
comparisons between preoperative diagnostic biopsies and RP specimens 
possible. The total number of cancer foci was charted as well as whether the 
RP specimen contained significant PC, defined as the presence of Gleason 
grade 4 or 5 patterns. An index tumor was identified for all patients: either the 
most dedifferentiated tumor or the largest tumor in the absence of Gleason 
patterns 4 or 5.  The largest tumor was designated based on the total 
continuous tumor area in consecutive histological sections. If extraprostatic 
extension or positive surgical margins were present—categorized simply as 
positive or negative—their location was charted and also whether they were 






The study population comprised 80 men who took part in the Finnish arm of 
the PRIAS trial and who, after being on surveillance for one year, underwent 
prostate MRI between February 2009 and May 2011 (Table 4). 
Table 4.  Disease characteristics of 80 study patients in Study III. Table modified from 
one published as ”Diffusion-weighted magnetic resonance imaging in prostate cancer 
patients on active surveillance one year after diagnosis and before repeat biopsy.” 
Vasarainen et al., in the Scandinavian Journal of Urology,© Acta Chirurgica Scandinavica 
Society, reprinted by permission of Taylor & Francis Ltd, on behalf of the Acta Chirurgica 
Scandinavica Society. 
Age at diagnosis, median (range) 64 (50-77) 
PSA at diagnosis (ng/ml), median (range) 5.7 (1.4-10.0) 
Prostate volume (ml), median (range) 44 (16-100) 
Diagnostic biopsy findings  
     Cancer in biopsies (mean), mm (%) 2.1 (1.2) 
     GS 6, n (%) 78 (97.5) 
     GS 7, n (%) 2 (2.5) 
MRI findings  
     Tumor visible on T2 images, n (%) 40 (50.0) 
     Tumor visible in ADC maps, n (%) 30 (37.5) 
Repeat biopsy findings  
     Cancer in biopsies (mean), mm (%) 5.0 (2.6) 
     No repeat biopsies, n (%) 2 (2.5) 
     No cancer, n (%) 30 (37.5) 
     GS 6, n (%) 37 (46.3) 
     GS 7, n (%) 10 (12.5) 






Study III looked at the performance of prostate MRI in detecting tumors of 
AS patients and predicting treatment change. Study patients, at the time of 
undergoing MRI, had all been on AS for one year and had repeat biopsies taken 
after the MRI, as required by the PRIAS surveillance protocol.  
MRI studies were performed with a 3 Tesla body-array scanner from 
Philips Medical Systems by use of a pelvic coil. In addition to T2-weighted 
images, echo-planar DW images and ADC maps were obtained.  The prostate, 
for interpreting the images, was divided into seven regions: anterior part, left 
apex, middle, and base and right apex, middle, and base. The T2-weighted 
images were first interpreted, and if any suspicious area was detectable, then 
the same region was further assessed in the corresponding DW images and 
ADC maps. Images were ranked as either positive or negative regarding 
suspicion of tumor. The patients subsequently underwent their repeat 
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biopsies, and correlations between MRI findings and repeat biopsy findings 




Study IV utilized the two clinical databases for all patients treated with RP 
between 1983 and 1998 at Helsinki University Hospital and between 2000 and 
2005 at Turku University Hospital. The Helsinki cohort originally comprised 
478 patients, of whom 358 were included in analyses. Turku University 
Hospital provided 532 patients, of whom 457 were included. These two cohorts 
were combined to form the final study cohort of 815 patients. Figure 14 
presents the selection process and Table 5 the patient characteristics. 
 
  
Figure 14 Forming the study cohort for Study IV. RP=radical prostatectomy, TMA=tissue 
microarray, ERG= ETS transcription factor, PTEN=Phosphatase and tensin homolog, 
IHC=immunohistochemistry. 
Table 5.  Characteristics of 815 patients in Study IV treated with radical prostatectomy 
between 1983 and 2005. Table modified from one published in Modern Pathology, 
29(12):1565-74 (2016), Lahdensuo et al., as ”Loss of PTEN expression in ERG-negative 
prostate cancer predicts secondary therapies and leads to shorter disease-specific survival 












Age at RP, years (mean, SD) (N = 815) 63.4 (5.9) 61.6 (5.8) 62.4 (5.9) 
Preoperative PSA, ng/ml (n, %) (n = 708) 
   
     ≤10.0 143 (50.5) 294 (69.2) 437 (61.7) 
     10.1-20.0 89 (31.4) 96 (22.6) 185 (26.1) 
     >20.0 51 (18.0) 35 (8.2) 86 (12.2) 
Gleason score at RP (n, %) (N = 815) 
   
     ≤6 93 (26.0) 168 (36.8) 261 (32.0) 
     7 207 (57.8) 197 (43.1) 404 (49.6) 
     8-10 58 (16.2) 92 (20.1) 150 (18.4) 
Grade group at RP (n, %) (N = 815)       
     1 93 (26.0) 168 (36.8) 261 (32.0) 
     2 93 (26.0) 134 (29.3) 227 (27.9) 
     3 114 (31.8) 63 (13.8) 177 (21.7) 
     4 45 (12.6) 70 (15.3) 115 (14.1) 
     5 13 (3.6) 22 (4.8) 35 (4.3) 
Pathological tumor stage (n, %) (n = 774) 
   
     2 202 (60.5) 233 (53.0) 435 (56.2) 
     3 (including three patients with T4) 122 (39.5) 207 (47.0) 339 (43.8) 
Lymph node status (n, %) (n = 806) 
   
     Negative 342 (97.2) 434 (95.6) 776 (96.3) 
     Positive 10 (2.8) 20 (4.4) 30 (3.7) 
ERG status in TMA (n, %) (N = 815) 
   
     Any core positive 181 (50.6) 228 (49.9) 406 (49.8) 
     Negative 177 (49.6) 229 (50.1) 409 (50.2) 
PTEN status in TMA (n, %) (N = 815) 
   
     Intact 164 (45.8) 338 (74.0) 502 (61.6) 
     Any loss 194 (54.2) 119 (26.0) 313 (38.4) 
     Complete loss 77 (21.5) 58 (12.7) 135 (16.6) 
AR status in TMA (n, %) (n = 358) 
   
     Low 127 (35.5) n.a. 
 
     High 231 (64.5) n.a. 
 








Death from any cause (n, %) (N = 815) 172 (48.0) 73 (16.0) 245 (30.0) 
Death from prostate cancer (n, %) (N = 815) 33 (9.2) 19 (4.2) 52 (6.4) 
Patients receiving secondary therapy after RP 
(n, %) (n = 796) 
124 (34.6) 136 (31.1) 260 (32.7) 
RP=radical prostatectomy 
SD=standard deviation 
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PSA=prostate-specific antigen 
ERG=ETS transcription factor 
TMA=tissue microarray 




Study IV looked into the value of tissue markers ERG, PTEN, and AR in 
predicting outcomes of patients after RP, utilizing two clinical databases with 
extensive preoperative and follow-up information and corresponding TMAs. 
These TMAs had been constructed between 2005 and 2010 at both clinics and 
later combined as part of a national PC-TMA-study initiative (FinnProstata 
IX). The TMAs had been constructed in slightly differing fashions: in Helsinki, 
two cores were obtained from the dominant Gleason pattern and one from the 
secondary pattern, whereas in Turku, a median of three cores were obtained 
from the index tumor, assigned primarily on the basis of degree of 
dedifferentiation. The Helsinki TMA slides had been stained and analyzed for 
AR expression and were further stained for ERG and for PTEN expression for 
the purposes of this study. The Turku TMA slides were stained for ERG and 
PTEN expression with the same antibodies and dilutions as in Helsinki, 
enabling combination of the cohorts. ERG and PTEN expression was, in each 
tissue core, evaluated by investigators blinded to the clinical and other 
pathological data. If PTEN loss was detectable, it was determined as either 
complete (=all patient’s cores negative) or partial (=any of a patient’s cores 
negative). 
For this study, the two clinical databases were combined and updated in 
2015 by the Finnish Cancer Registry's data on patients’ all-cause and disease-
specific mortality. Information on possible secondary therapies after RP came 
from patient records.  The decision to administer secondary therapies after RP 
was that of the treating urologists, according to current clinical practices. The 
association of marker expression status with clinical variables and survival was 
then analyzed. 
4.2 STATISTICAL ANALYSES 
All statistical analyses were performed with IBM SPSS Statistics versions 17-
23 (IBM, Chicago, IL, USA) and Stata/SE 12.0 (StataCorp LP, College Station, 










Annual bacteremia incidences came from dividing the number of bacteremic 
complications annually by the number of biopsy procedures performed in the 
same year. Confidence intervals of 95% (95% CI) for annual bacteremia rates 
were calculated by Wilson score. Calendar year of biopsy, patient age at biopsy, 
and serial number of the biopsy session were included as independent 
variables in a multiple regression analysis of all biopsies to discover possible 
risk factors for developing any bacteremia or bacteremia caused by a FQ-
resistant bacterium in the entire biopsy cohort. Possible risk factors for 
bacteremia with FQ-resistant bacteria in the bacteremic cohort were studied, 
for the 107 patients with available medical records, by means of Pearson’s and 





Pearson’s chi-squared test was employed to evaluate the performance of 
biopsies in predicting tumor location in RP specimens. The correlation 
between extent of cancer in biopsies and RP specimens was studied with the 
aid of Spearman’s rank order correlation and linear regression analysis. In 
linear regression analysis, the dependent variable was the squared percentage 
of cancer in the RP sextant. The square root of the dependent variable served 




Spearman’s rank order correlation and Pearson’s chi-squared test were 
employed to study whether any clinical variable correlated with the tumor’s 
being visible on MRI. The association of tumor location sextant-wise between 
MRI and repeat biopsies was also tested with Pearson’s chi-squared test.  
Visualizations of tumors on either standard T2 images or ADC maps were 
included in a multivariate logistic regression model predicting deferred radical 
treatment, along with patient age, PSA level at diagnosis, PSA density at 
diagnosis, percentage of cancer in diagnostic biopsies, PSA doubling time, and 




The correlation between ERG and PTEN expression status and clinical 
variables was explored with Pearson’s and Fisher’s chi-squared tests. Kaplan-
Meier survival analyses with Mantel-Cox log rank statistics and uni- and 
multivariate Cox regression analyses compared various marker expressions 
for their effects on disease-specific survival (DSS), overall survival (OS); and, 
for the Helsinki cohort, secondary-therapy-free survival. Standard variables–
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age at surgery, preoperative PSA, pathological tumor stage, Gleason score, and 
lymph node status–were also included in the Cox regression models. 
4.3 ETHICS 
Data for Studies I, II, and IV were gathered retrospectively from patient 
records, laboratory archives, and from the Finnish Cancer Registry (Study IV), 
before anonymization, without requiring informed consent from patients. 
Study III was conducted as part of the prospective PRIAS trial, in which 
patients had given informed consent at enrollment.  
All studies were approved by the Ethics Committee of the Helsinki and 
Uusimaa Hospital District. In addition, the inclusion of patients from Turku 
University Hospital in Study IV was approved by the Ethics Committee of the 
Hospital District of Southwest Finland. For Study IV, use of tissue materials 
was approved by the National Supervisory Authority for Welfare and Health 
(Valvira), and the Cancer Registry’s data by the National Institute for Health 






5.1 STUDY I 
The average incidence of post-biopsy bacteremias in our hospital district 
between 2005 and 2013 was 0.7% (111 of 17 183 biopsies, or 7 bacteremic 
complications per 1000 biopsies). The incidence increased from 0.5%, or 5 
bacteremic complications per 1000 biopsies, in 2005 (95% CI 0.3-0.9) to 1.2%, 
or 12 bacteremic complications per 1000 biopsies, in 2012 (95% CI 0.8-1.8). 
Concurrently, the percentages of FQ-resistant Escherichia coli blood isolates 
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Figure 15 Increasing rates of bacteremias after transrectal prostate biopsies and 
fluoroquinolone(FQ)-resistance of Escherichia coli blood isolates of over 20-year-old men in 
the Helsinki and Uusimaa hospital district during 2005–2013. Figure published in Prostate 
Cancer and Prostatic Diseases, 19, 417-422 (2016), Lahdensuo et al., ”Increase of prostate 
biopsy-related bacteremic complications in southern Finland, 2005–2013: a population-based 
analysis”, by permission from Macmillan Publishers Ltd. 
In examination of risk factors for developing post-biopsy bacteremia in the 
biopsy cohort, a previous biopsy session and later calendar year of biopsy 
significantly raised the risk, according to univariate logistic regression 
analysis. Only later calendar year of biopsy, however, remained statistically 
significant in multivariate analysis (Table 6). 
Table 6. Logistic regression analyses for risk of developing post-biopsy bacteremia in the 
biopsy cohort (17183 biopsies during 2005–2013). Table modified from one published in 
Prostate Cancer and Prostatic Diseases, 19, 417-422 (2016), Lahdensuo et al., ”Increase of 
prostate biopsy-related bacteremic complications in southern Finland, 2005–2013: a 




OR 95% CI P OR 95% CI P 
Calendar year of biopsy 1.164 1.079 1.255 <0.000 1.155 1.070 1.247 <0.000 
Increasing serial number 
of biopsy session 1.232 1.020 1.488 0.030 1.174 0.969 1.423 0.101 
Patient age at biopsy 1.006 0.985 1.027 0.575 1.004 0.982 1.025 0.746 
OR=odds ratio 
CI=confidence interval         
 
These regression analyses were repeated for those patients who had 
bacteremia caused by FQ-resistant bacteria, but none of these variables was 
statistically significant. 
For the bacteremic cohort of 107 patients whose medical records provided 
possible clinical risk factors, Pearson’s and Fisher’s chi-squared tests revealed 
that foreign travel within the three preceding months was statistically 
significantly associated with development of bacteremia caused by FQ-
resistant bacteria. This was also a statistically significant risk factor in exact 
logistic regression (Table 7). The 95% CI started from above one and extended 
to infinity, most likely because of the lack of patients with a history of recent 










Table 7. Univariate and multivariate analyses of risk factors for developing bacteremia 
with fluoroquinolone(FQ)-resistant bacteria in the bacteremic cohort. Table modified from 
one published in Prostate Cancer and Prostatic Diseases, 19, 417-422 (2016), Lahdensuo 
et al., ”Increase of prostate biopsy-related bacteremic complications in southern Finland, 
2005–2013: a population-based analysis”, by permission from Macmillan Publishers Ltd. 
 Univariate Multivariate
a 









(n  =  55) 
P OR 95% CI P 
Repeat biopsy 18 (34.6%) 16 (29.1%) 0.678b 1.355 0.521–3.569 0.638 
Antibiotic treatment 
within three months 8 (15.4%) 4 (7.3%) 0.228b 3.485 0.702–23.695 0.154 
Foreign travel within 
three months 6 (11.5%) 0 (0%) 0.011c 9.144 1.238–infinite 0.028 
Diabetes 7 (13.5%) 16 (29.1%) 0.061b 0.330 0.091–1.041 0.060 
Immunosuppressive 
medication 3 (5.8%) 1 (1.8%) 0.354c 4.371 0.331–238.21 0.395 
Indwelling or 
suprapubic catheter 1 (1.9%) 3 (5.5%) 0.618c 0.242 0.003–4.332 0.557 
aExact logistic regression, bPearson's chi-squared test, cFisher's exact test, because of 
expected cell frequencies of less than five 
 
   FQ=fluoroquinolone 
   OR=odds ratio 
   CI=confidence interval 
5.2 STUDY II 
Standard 12-core biopsies performed poorly in predicting tumor location.  
When analyzed by prostate sextant, the concordance of cancer locations 
between biopsies and RP specimens was modest (Table 8).  
Table 8. Sextant distributions of cancer in diagnostic biopsies and radical prostatectomy 
(RP) specimens of 96 patients. Percentages in Biopsy and RP columns exceed 100% in 
total, because patients harbored cancer in multiple sextants. Table modified from one 
published in ”Performance of transrectal prostate biopsies in detecting tumours and 
implications for focal therapy”, Lahdensuo et al., Scandinavian Journal of Urology,© Acta 
Chirurgica Scandinavica Society, reprinted by permission of Taylor & Francis Ltd, on behalf 
















Left 41 (42.7) 29 (30.2) 48.3 59.7 34.1 72.7 
Right 48 (50.0) 41 (42.7) 58.5 56.4 50.0 64.6 
Middle 
Left 41 (42.7) 74 (77.1) 48.6 77.3 87.8 30.9 
Right 50 (52.1) 78 (81.3) 57.7 72.2 90.0 28.3 
Apex 
Left 40 (41.7) 73 (76.0) 46.6 73.9 85.0 30.4 




NPV=negative predictive value 
PPV=positive predictive value 
 
Sensitivities and specificities of diagnostic biopsy were also unsatisfactory. 
Disease locations predicted by biopsy appeared to be evenly distributed 
between the sextants, but analysis of RP specimens revealed tumors to be 
dominantly in the middle and apex. A positive needle biopsy from the base 
overestimated the prevalence of disease, i.e. this region yielded the greatest 
number of false-positive results, and conversely, a biopsy from the apex 
underestimated the prevalence. The PPV and NPV of a test are dependent on 
the true prevalence; consequently, the low true prevalence—based on RP 
findings—of tumors in the base of the prostate led to a low PPV and a fairly 
high NPV for positive biopsies from the base. The opposite applied to apical 
tumors, which were prevalent in RP specimens, but went underdetected by 
biopsy. This improved the PPV and impaired the NPV of a positive biopsy 
finding from the apex of the prostate. 
Standard 12-core biopsies were also inaccurate in predicting unilateral 
disease. Of the 47 cases, only 11 (23.4%) that were presumed on biopsy to be 
unilateral, were, in analysis of RP specimens, actually unilateral. More 
puzzlingly, biopsies predicted bilateral disease for the 7 patients who in reality 
had cancer confined to only one lobe. This is most likely explained by the 
biopsy needle’s inadvertently crossing the midline of the prostate.  
In comparisons of the extent of cancer sextant-wise between biopsies and 
RP specimens by Spearman’s rank order analysis, both the length and 
percentage of cancer in biopsy cores correlated positively with the percentage 
of cancer in the RP specimen. This correlation was statistically significant in 
the apex and middle of the prostate, but not in the base, probably because of 
the low prevalence of cancer there. The positive correlation of cancer extent 
between biopsies and RP specimens was also corroborated in linear regression 
analysis (Table 9).  
Table 9. Correlations of extent of cancer between biopsies and radical prostatectomy 
specimens per sextant with linear regression analysis. Analyses performed separately with 
cancer length (mm) in biopsies and cancer percentage (%) in biopsies as independent 
variables. Table modified from one published in ”Performance of transrectal prostate biopsies 
in detecting tumours and implications for focal therapy”, Lahdensuo et al., Scandinavian 
Journal of Urology,© Acta Chirurgica Scandinavica Society, reprinted by permission of Taylor 







95% CI p 
Correlations using length of cancer (mm) in biopsy cores 
Base 
Left 0.74 0.33-1.15 0.11 0.00-0.22 0.043 
Right 0.92 0.55-1.29 0.08 0.00-0.15 0.033 
Middle Left 1.94 1.50-2.37 0.25 0.14-0.36 <0.001 
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Right 2.39 1.91-2.86 0.19 0.09-0.28 <0.001 
Apex 
Left 2.45 1.95-2.95 0.16 0.05-0.27 0.005 
Right 2.55 2.05-3.06 0.26 0.14-0.37 <0.001 
Correlations using percentage of cancer (%) in biopsy cores 
Base 
Left 0.77 0.35-1.18 0.16 -0.02-0.33 0.073 
Right 0.93 0.56-1.30 0.13 0.00-0.25 0.043 
Middle 
Left 1.98 1.54-2.41 0.36 0.19-0.53 <0.001 
Right 2.38 1.91-2.86 0.31 0.15-0.47 <0.001 
Apex 
Left 2.48 1.99-2.97 0.24 0.07-0.41 0.007 
Right 2.53 2.04-3.02 0.43 0.25-0.61 <0.001 
CI=confidence interval 
 
The higher constant coefficients for tumors in the middle and apex of the 
prostate further highlighted their higher prevalence. 
In further analysis of RP specimens, the majority of the 96 patients, 74  
(77.1%) had multifocal disease, i.e. two or more tumor foci. Cancer foci were 
considered as being significant PC in the presence of a Gleason grade 4 or 5 
pattern, resulting in 81 patients (84.4%) with significant tumors. In examining 
the prevalence and distribution of significant PC, of the 81 patients, 36 (44.4%) 
had significant PC confined to one side of the prostate; 39 (48.1%) had solitary 
significant tumors, i.e. these patients’ other cancer foci exhibited solely a 
Gleason grade 3 pattern. 
Index tumors chosen from each RP specimen had their morphologies 
studied separately. The index tumors were mostly unilateral (81 of 96, 84.4%), 
i.e. confined to one side of the prostate. Sizewise, these index tumors presented 
in one sextant in 45 (46.9%) specimens, with 51 (53.1%) extending to two or 
more adjacent sextants (Table 10). 
Table 10.  Detailed pathological findings of 96 patients at radical prostatectomy. Table 
modified from one published in ”Performance of transrectal prostate biopsies in detecting 
tumours and implications for focal therapy”, Lahdensuo et al., Scandinavian Journal of 
Urology,© Acta Chirurgica Scandinavica Society, reprinted by permission of Taylor & Francis 
Ltd, on behalf of the Acta Chirurgica Scandinavica Society. 
 n 
(%, of 96, unless 
stated otherwise) 
Tumor foci per patient   
     1 22 22.9 
     2 21 21.9 
     3 34 35.4 
  ≥ 4 19 19.8 
Significant disease (presence of  
Gleason grade 4 or 5) 81 84.4 
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Only one significant tumor, n (% of 81 cases) 39 48.1 
Tumor laterality   
     Unilateral any PC 18 18.8 
     Bilateral any PC 78 81.3 
     Unilateral significant disease,  
      n (% of 81 cases) 36 44.4 
     Unilateral index tumor 81 84.4 
     Index tumor extending over midline 15 15.6 
Index tumor characteristics   
     GS 3+3 15 15.6 
     GS 3+4 55 57.3 
     GS 4+3 17 17.7 
     GS ≥ 8 9 9.4 
     Extraprostatic extension, n (% of 16 cases) 14 87.5 
     Positive surgical margins, n (% of 26 cases) 23 88.5 
PC=prostate cancer  
GS=Gleason score 
5.3 STUDY III 
Of the 80 patients who underwent prostate MRI after one year on surveillance, 
only 50% had MRI-visible tumors. No clinical variable: patient age, prostate 
volume, diagnostic PSA, percentage of cancer at diagnostic biopsy, PSA 
doubling time, or PSA at discontinuation, correlated with MRI visibility in 
Spearman’s rank order correlation. This was also explored with Pearson’s chi-
squared test with slightly different clinical variables: Gleason score at 
diagnostic or repeat biopsy, number of positive cores at diagnostic or repeat 
biopsies, or discontinuation of AS, with no statistically significant findings. 
This analysis was also repeated for the subgroup of 23 patients who had 
disease progression in repeat biopsy or who discontinued AS, but this, again, 
revealed no statistically significant associations.  
When comparing cancer locations sextant-wise between MR images and 
subsequent repeat biopsies, Pearson’s chi-squared test revealed a statistically 
significant association only for tumor location between right mid-gland in 
MRI and right base in repeat biopsy (Table 11). 
Table 11. P-values for associations of sextant-wise cancer locations between magnetic-
resonance imaging (MRI) (vertical) and repeat biopsy (horizontal) findings with Pearson’s 
chi-squared test. Table modified from one published in ”Diffusion-weighted magnetic 
resonance imaging in prostate cancer patients on active surveillance one year after 
diagnosis and before repeat biopsy”, Vasarainen et al., Scandinavian Journal of Urology,© 
Acta Chirurgica Scandinavica Society, reprinted by permission of Taylor & Francis Ltd, on 





biopsies Left base Left middle Left apex Right base Right middle Right apex 
Left base 0.409 
     
Left middle 0.545 0.059 




   
Right base 












At the time of analysis, 23 patients had discontinued AS, 19 due to 
progression on repeat biopsies and 4 to decreasing PSA-doubling time. In 
logistic regression analysis, which included tumor visibility on T2-images or 
ADC maps, the only variable statistically significant for predicting treatment 
change was PSA at the time of discontinuation (Table 12). 
Table 12. Logistic regression analysis of variables predicting discontinuation of active 
surveillance. Table modified from one published in ”Diffusion-weighted magnetic resonance 
imaging in prostate cancer patients on active surveillance one year after diagnosis and 
before repeat biopsy”, Vasarainen et al., Scandinavian Journal of Urology,© Acta Chirurgica 
Scandinavica Society, reprinted by permission of Taylor & Francis Ltd, on behalf of the Acta 
Chirurgica Scandinavica Society. 
 p OR (95% CI) 
Patient age 0.057 0.9 (0.7-1.0) 
PSA at diagnosis 0.371 0.8 (0.4-1.4) 
PSA density at diagnosis 0.921 1.0 (1.0-1.0) 
Percentage of cancer at diagnostic biopsy 0.199 1.8 (0.7-4.3) 
PSA-doubling time 0.921 1.0 (1.0-1.0) 
PSA at time of discontinuation 0.002 1.8 (1.2-2.6) 
Tumor visible on T2 images 0.273 3.4 (0.4-30.1) 




ADC=apparent-diffusion coefficient  
5.4  STUDY IV 
Crosstab analyses revealed that complete loss of PTEN expression was 
significantly associated with several clinical variables that indicate more 
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aggressive PC, such as higher Gleason score, higher pathological tumor stage, 
and positive lymph nodes. It was also associated with poorer OS and DSS and 
increased likelihood of receiving secondary treatment after RP. Positive ERG 
status, however, correlated only with lower preoperative PSA and increased 
likelihood of receiving secondary therapy but not with DSS or OS (Table 13).  
Table 13. Correlations of ERG and PTEN expressions with clinical variables by Pearson’s 
and Fisher’s chi-squared tests for 815 patients treated with radical prostatectomy. Table 
modified from one published as electronic supplementary material to accompany ”Loss of 
PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads 
to shorter disease-specific survival time after radical prostatectomy”, Lahdensuo et al., 
Modern Pathology, 29(12):1565-74 (2016), by permission from Macmillan Publishers Ltd. 
 












(N = 815) 
680 (83.4) 135 (16.6) ‒ 409 (50.2) 406 (49.8) ‒ 
Preoperative 
PSA 
(n = 708) 
    
0.363a 
    
0.042a 
≤ 10.0 ng/ml 372 (85.1) 65 (14.9) 237 (54.2) 200 (45.8) 
10.1-20.0 ng/ml 157 (84.9) 28 (15.1) 88 (47.6) 97 (52.4) 
> 20.0 ng/ml 68 (79.1) 18 (20.9) 35 (40.7) 51 (59.3) 
Gleason score 
(N = 815)   
  
0.000a 
    
0.102a ≤ 6 243 (93.1) 18 (6.9) 117 (44.8) 144 (55.2) 
7 337 (83.4) 67 (16.6) 215 (53.2) 189 (46.8) 
≥ 8 100 (66.7) 50 (33.3) 77 (51.3) 73 (48.7) 
Pathological 
tumor stage 
(n = 774)   
  
0.000a 
    
0.070a 
2 392 (90.1) 43 (9.9) 203 (46.7) 232 (53.3) 
3 254 (75.6) 82 (24.4) 184 (54.8) 152 (45.2) 
4 1 (33.3) 2 (66.7) 1 (33.3) 2 (66.7) 
Lymph node 
involvement 
(n = 806)   
  
0.000b 
    
0.353b 
Yes 15 (50.0) 15 (50.0) 18 (60.0) 12 (40.0) 
No 659 (84.9) 117 (15.1) 387 (49.9) 389 (50.1) 
Secondary 
therapy after RP  











Yes 177 (68.1) 83 (31.9) 146 (56.2) 114 (43.8) 
No 484 (90.3) 52 (9.7) 252 (47) 284 (53) 
Overall survival 
(N = 815) 
   
0.001b 
    
0.446b 
All-cause death 188 (76.7) 57 (23.3) 128 (52.2) 117 (47.8) 
Alive 492 (86.3) 78 (13.7) 281 (49.3) 289 (50.7) 
Disease-specific 
survival 










1.000b Death due to 
prostate cancer 
36 (69.2) 16 (30.8) 26 (50.0) 26 (50.0) 
Alive or all-
cause death 
644 (84.4) 119 (15.6) 380 (49.8) 383 (50.2) 
a Pearson Chi-squared test, b Fishers-exact test 
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PTEN=Phosphatase and tensin homolog 




Performing Kaplan-Meier analyses with ERG status alone revealed no 
associations with OS, DSS, or time until the patient received secondary 
therapy. PTEN expression status was unable to predict OS, but both partial 
and complete PTEN loss was statistically significantly associated with shorter 
DSS time (Figure 16).  
 
Figure 16 Both partial (A) and complete (B) loss of PTEN expression led to shortened disease-
specific survival times. Figure previously published in Modern Pathology, 29(12):1565-74 
(2016), Lahdensuo et al., ”Loss of PTEN expression in ERG-negative prostate cancer 
predicts secondary therapies and leads to shorter disease-specific survival time after radical 
prostatectomy”, by permission from Macmillan Publishers Ltd. 
Complete loss of PTEN expression, when compared with intact or partially 
lost PTEN, raised the risk of PC death with a hazard ratio (HR) of 2.16 (95% 
CI 1.17-3.98, P=0.014) in univariate Cox regression analysis, although not in 
multivariate analysis. In the multivariate analysis, only positive lymph nodes 
or pathological tumor stage >2 statistically significantly raised the risk of PC 
death. Risk of PC death was also raised for patients with high AR expression 
status, but only in univariate analysis (HR 2.38, 95% CI 1.01-5.60, P=0.048). 
Marker expression status failed to associate with increased risk of death from 
any cause in uni- or multivariate analysis. Complete PTEN loss raised the risk 
for receiving secondary therapies after RP in both uni- and multivariate 
analysis (HR 2.78, 95% CI 1.85-4.19, P<0.001 and HR 2.29, 95% CI 1.31-3.99, 
P=0.003, respectively). 
The association of combined ERG/PTEN expression status with the 
likelihood of receiving secondary treatment after RP was explored with 
Kaplan-Meier analyses. Complete loss of PTEN expression was associated with 
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shorter secondary-therapy-free survival in both ERG-positive and ERG-
negative patients. Complete PTEN loss in ERG-negative patients was 
significantly associated with shorter DSS time when compared to ERG-
positive patients with PTEN intact or only partially lost (Figure 17). 
 
Figure 17 Association of combined ERG and PTEN expression status with (A) survival until 
seconday therapies and (B) disease-specific survival. Figure previously published in Modern 
Pathology, 29(12):1565-74 (2016), Lahdensuo et al., ”Loss of PTEN expression in ERG-
negative prostate cancer predicts secondary therapies and leads to shorter disease-specific 
survival time after radical prostatectomy”, by permission from Macmillan Publishers Ltd. 
The utility of combined ERG/PTEN status in stratifying patients with 
intermediate-grade PC (Gleason score 7 or Grade group 3) was also assessed 
with Kaplan-Meier analysis. For these subgroups–similar to findings for the 
entire cohort–negative ERG expression coupled with complete PTEN loss led 





Figure 18 Association of combined ERG and PTEN expression status with disease-specific 
survival times in (A) Gleason score 7 subgroup and (B) Grade group 3. Figure previously 
published in Modern Pathology, 29(12):1565-74 (2016), Lahdensuo et al., ”Loss of PTEN 
expression in ERG-negative prostate cancer predicts secondary therapies and leads to 
shorter disease-specific survival time after radical prostatectomy”, by permission from 
Macmillan Publishers Ltd. 
The effect of AR expression status in ERG-positive and ERG-negative 
cancers with PTEN loss was also tested. Of the ERG-negative patients, 52% 
(92 of 177) showed high AR expression, compared to 76.8% (139 of 181) of the 
ERG-positive patients. In Kaplan-Meier analysis, ERG-negative patients with 
high AR expression had a significantly shorter DSS time than did ERG-
negative patients with low AR expression. This shorter DSS time among ERG-
negative patients with high AR was further accentuated by their complete loss 
of PTEN, and a similar effect occurred in analysis of the subgroup of Gleason 
score 7 patients (Figure 19). For ERG-positive patients, AR status failed to 
determine survival differences, nor did differences emerge among patients 




Figure 19 Association of combined marker statuses with disease-specific survival (DSS) time. 
(A) AR status stratified patients regarding DSS time for ERG-negative cases. (B) Complete 
PTEN loss was associated with shorter DSS time for ERG-negative patients with high AR 
expression. (C) Same analysis as in figure B, but for Gleason score 7 patients. Figure 
published in Modern Pathology, 29(12):1565-74 (2016), Lahdensuo et al., ”Loss of PTEN 
expression in ERG-negative prostate cancer predicts secondary therapies and leads to 
shorter disease-specific survival time after radical prostatectomy”, by permission from 





6.1 MAIN FINDINGS AND DISCUSSION OF SUBSTUDIES 
Study I 
 
The rise in the incidence of post-biopsy bacteremias over the 9-year study 
period was 2.4-fold, which may be explained by several factors. Similar rising 
trends have been noted in other countries as well and have been linked to the 
concomitant rise in FQ resistance of enteric bacteria. Interestingly, half the 
causative organisms responsible for bacteremias in our material were FQ 
resistant, and the rest were FQ susceptible. This finding has brought to our 
attention shortcomings in implementing proper antibiotic prophylaxis for the 
biopsy procedure. The evident rising incidence of bacteremias may be in part 
a result of the evolving clinical practice of ordering blood cultures more 
actively for febrile patients now that urologists’ awareness of serious post-
biopsy complications has improved.  
One important finding is that, in multivariate analysis, repeat biopsies did 
not elevate the risk for bacteremic infections. Repeat biopsies may predispose 
the patient to an increased risk for infectious complications, but evidence is 
already robust to counter this (Loeb et al. 2013a, Aly et al. 2015, Bokhorst et 
al. 2016a, Halpern et al. 2017). This is reassuring, considering that AS 
protocols rely heavily on repeat biopsies (Bruinsma et al. 2016) with the 
protocols at Johns Hopkins and the University of Miami even mandating 
biopsies annually.  
Urologists need to be aware of the rising incidence of post-biopsy infectious 
complications. The possibility of developing an infectious complication 
requiring hospitalization–and hospital admission rates have been as high as 
6.9% (Loeb et al. 2013b, Borghesi et al. 2017)–should be mentioned when 
discussing prostate biopsies with a patient. Prior to the procedure, the 
patient’s possible predisposing risk factors for infections, especially diabetes 
(Simsir et al. 2010, Loeb et al. 2012, Halpern et al. 2017) and urinary catheters 
(Simsir et al. 2010, Eruz et al. 2017), need assessment. If the patient has 
recently traveled abroad (Patel et al. 2012), he should not receive the standard 
FQ prophylaxis but instead an alternative antibiotic or should be considered 
for targeted prophylaxis based on a pre-biopsy rectal swab (Duplessis et al. 
2012, Taylor et al. 2012, Roberts et al. 2014, Cussans et al. 2016, Li et al. 2016). 
Having previously undergone a biopsy procedure need not be considered a risk 
factor for post-biopsy infections.    
Limitations of this study include its retrospective design and its including 
information on only blood-culture-positive post-biopsy infections. Collecting 
data prospectively, ideally with patient-reported outcomes, would have 
provided a more comprehensive view of the occurrence of infectious 
 
73 
complications, not just blood-culture-positive infections. Lack of data on the 
number of negative blood cultures also prevents us from drawing definitive 
conclusions regarding our region’s rising bacteremia-incidence trend and its 
underlying causes. Because the annual numbers of all blood cultures—positive 
and negative—were unknown, we are unable to rule out of the increasing 
incidence figures the role of urologists’ ordering blood cultures more actively. 
This limitation was acknowledged during data acquisition, but extracting data 
on all blood cultures—positive and negative—during the observation period 
proved technically too challenging and had to be abandoned. The study’s 
strengths derive from the comprehensive patient registries, which have 
covered the 9-year observation period for the entire hospital district and 




The study confirmed that random biopsies are unreliable in predicting 
sextant-wise prostate tumor location and unilateral disease. These 
shortcomings make random biopsies a poor tool for detailed planning of 
radical therapies such as RP or RT. Not only did biopsies accurately predict 
unilateral disease in only one-fourth of the patients with unilateral disease at 
RP, but, puzzlingly, for 7% of patients, the biopsies predicted bilateral disease 
when it was actually unilateral. Similarly discouraging findings had occurred 
earlier, before our own data gathering (Schulte et al. 2008, De Laet et al. 2009, 
Gallina et al. 2012, Iremashvili et al. 2012, Washington et al. 2012), so we were 
interested in whether this held true for us. That our results are in line with 
those of other institutions indicates that our practices do not markedly differ 
from theirs.  
The poor performance of 12-core biopsies is disheartening, but instead of 
abandoning the procedure, efforts should focus on improving it. Young 
doctors need proper training, with sufficient biopsy procedures performed 
under supervision to ensure that systematic errors do not occur. Active 
communication between the person taking the biopsies and the one placing 
the cores in specimen jars is key to ensuring correct sorting and labeling. The 
incorporation of a check list–similar to ones already in routine use in 
operating rooms—which ensures that all personnel involved with taking the 
biopsy know the required equipment and procedure stages, could also help to 
minimize errors in sampling and specimen handling. Finally, the placement of 
needles in the prostate could be routinely documented by registering devices 
such as those for fusion of US and MR images.    
The sextant-wise analysis of RP specimens revealed that PC is rarely found 
in the base of the prostate and is more prevalent in the middle and apex. 
Although this is not widely studied, similar findings have emerged (Mai et al. 
2002, Takashima et al. 2002, Ishii et al. 2007). Biopsies overestimated the 
prevalence of cancer in the base of the prostate, leading to low PPVs for 
positive biopsy from the base. This is most likely due to a systematic error in 
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the biopsy procedure, where the needle fails to be inserted adequately deeply 
in the prostate due to the aim of avoiding unnecessarily sampling the seminal 
vesicles or puncturing the bladder neck and causing bleeding (Figure 5C).   
Our statistical analyses indicate that the extent of cancer in biopsy cores 
correlates positively with extent of cancer in the corresponding RP-specimen 
sextant, but the clinical significance of our finding is less clear. It is possible 
that the strengthening of the positive correlation as we move from the base to 
the apex is more indicative of the concurrent increasing prevalence of tumors 
in the craniocaudal direction. The lower prevalence of tumors in the base is 
possibly explained by the zonal anatomy of the prostate. The peripheral zone, 
where most PC arises, extends to the base only in the posterior part of the 
prostate (Figure 6). Likewise, the transitional zone, the second-most common 
origin zone for PC, does not reach the base. The base is therefore mostly 
comprised of the central zone and fibromuscular stroma. This could explain 
the low prevalence of PC in the base. 
In further assessment of tumor morphology, half the patients with 
significant PC had only one significant lesion, which would hypothetically 
make these patients candidates for focal therapies of such lesions. Around 40% 
of our patients with significant PC had their significant disease confined to one 
side, making them candidates for possible hemiablative techniques. Random 
12-core biopsies are, however, not nearly reliable enough for planning of such 
tissue-sparing techniques.  
Most cases of extraprostatic extension and positive surgical margins at RP 
were extensions of the index tumor. Choice of index tumors was based on 
degree of dedifferentiation as opposed to the more common criterion of tumor 
volume (van der Kwast et al. 2011). With these criteria, we were able to 
pinpoint those tumors that had caused unfavorable outcomes at RP. This 
should encourage the practice of assigning the index tumor based primarily on 
degree of dedifferentiation, and only secondarily on tumor size. 
The limited performance of biopsies in our study raises the question of the 
role of random biopsies in the diagnosis and treatment planning of PC patients 
today. Urologists should be aware of shortcomings in predicting tumor 
location and extent and avoid relying too heavily on biopsies in the risk 
stratification of patients. It is this uncertainty that has made urologists ready 
to adopt prostate MRI in the diagnosing and staging of localized PC, because 
MRI appears to be more reliable in estimating disease location and even its 
aggressiveness. For the time being, however, random biopsies are the first-line 
tool for diagnosing PC until prostate MRI becomes more readily accessible and 
affordable. Prostate MRI may someday make random biopsies redundant, 
because possible MRI-visible lesions can consequently be sampled with MRI-
targeting techniques. The objective of this approach would be the accurate 
detection of clinically significant disease while leaving apparently low-grade 
tumors undiagnosed. If radical therapies are later planned, the patients will 
then already have undergone prostate MRI, useful in planning of nerve-
sparing RP or treatment fields for RT with greater reliability than with current 
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random biopsies. MRI is, however, also an imperfect tool for this purpose. A 
2016 meta-analysis has shown the sensitivity and specificity of overall 
detection of T3 disease—pooling results from 38 studies—to be 61% and 88% 
(de Rooij et al. 2016).    
Our findings came from a fairly small number of patients, which may limit 
generalizability. A potential source of bias in comparing tumor locations 
sextant-wise is the assignment of sextant divisions differing between the 
persons taking the biopsies. Our analysis also did not take prostate volume 
into account, although sampling very small and very large prostates have their 
own challenges. The study’s strengths are in the reliability of the data because 
of standardized biopsy protocols and specimen-handling procedures as well as 




Study III can be viewed as a report of our early experiences with prostate MRI. 
We were interested in evaluating how prostate MRI would perform as a follow-
up tool for patients on AS at our institution and whether it would bring 
additional value. 
PC was visible on MRI for only half these patients. This is in line with the 
fact that these patients all harbored low-risk PC. Tumor MRI visibility showed 
no positive correlation with any clinical or pathological finding that could 
possibly indicate greater tumor burden, nor did it correlate with 
discontinuation of AS; the latter was somewhat surprising. MRI reports were 
available to the treating urologists when the patients came in for their repeat 
biopsies. What could therefore have been expected is that an MRI-visible 
tumor would affect decision-making towards discontinuation of AS, but this 
again reflects how unacquainted urologists were with prostate MRI and its 
significance at the time. Today we know that the PPV of an MRI-visible lesion 
for accurately detecting clinically significant PC is modest. The PROMIS study 
has found the PPV to be 65%, while a 2015 review has reported it to range 
between 34 and 93% (Fütterer et al. 2015). The decision to discontinue AS and 
advance to radical therapy should therefore not be made solely because of an 
MRI-visible tumor; histological confirmation with biopsy of higher-grade 
disease is, for the time being, mandatory.   
When a tumor was visible on MRI, its location correlated poorly with the 
tumor location estimated by prostate biopsies. This is more likely a reflection 
of the inaccuracy of prostate biopsies than of MRI shortcomings. 
In our study, MRI lacked value as a follow-up tool for AS patients, and the 
information it offered failed to influence clinical treatment choices. Based on 
the study findings, prostate MRIs were not ordered for AS patients at our clinic 
for some years. The study taught us that even though the patient population 
was homogenous, and the question regarding MRI–“Is the cancer visible on 
MRI or not?”–was well defined, performing MRIs with suboptimal techniques 
and inadequate standardization would likely be of limited value. Prostate MRI 
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has since developed enormously, however. The uroradiologists at our 
institution now show a great deal of interest in prostate MRI, and both 
versions of the PI-RADS system have been adopted into clinical practice: 
version 1 in 2012 and version 2 in 2015. This means that prostate MRI is 
currently performed with multiparametric techniques and has been reported 
in a standardized and structured format since 2012. As a result, prostate MRI 
is now more informative and is readily ordered for AS patients. At our 
institution, its timing is most commonly immediately after diagnosis of PC 
either to exclude the presence of significant PC or in the same setting as in our 
study, meaning before repeat or confirmatory biopsies. For PRIAS patients it 
is also employed when the surveillance protocol mandates extra measures 
because of decreased PSA-doubling time. Patients who take part in the PRIAS 
study and who have prostate MRI as part of their follow-up are currently 
included in the ongoing prospective PRIAS-MRI side-study (Hoeks et al. 
2014). It will be interesting to see how the implementation of PRECISE 
guidelines for reporting of MRI for patients on AS (Moore et al. 2017) will 
affect radiological practices and AS-patient treatment. 
An obvious limitation to the validity of our findings stems from the 
methods by which prostate MRIs were conducted and assessed. The MRIs 
were performed without much previous experience and before local 
standardization of imaging techniques. Compared to imaging standards today, 
the DWI was then performed with inadequately low b values and with no 
dynamic-contrast enhancement–a requirement for mpMRI. The radiological 
assessment of images also lacked current standardization, but at least all of the 
images were viewed by the same uroradiologist. One strength of our study is 
that the MRIs were performed on a homogenous patient population: patients 
with only low-volume, low-grade PC, all studied after one year on surveillance 
and before their repeat biopsies; this eliminated any possible effects on the 




The main finding was that complete loss of PTEN expression raised the risk of 
PC death and the risk for receiving secondary therapies after RP. As a single 
biomarker, complete loss of PTEN expression appears the most promising 
indicator of disease progression for clinical use, because of its strong 
association with required secondary therapies after RP and shortened DSS 
time. Another finding was that, in regard to DSS, ERG-negative-PTEN-
negative patients with high AR expression had the poorest outcomes. We can 
only speculate on the underlying mechanisms: based on other reports, it 
appears that in the absence of TMPRSS2:ERG fusion, some as-yet poorly 
defined factors contribute to activating AR-signaling and promote PC 
progression (Culig et al. 1994, Sahu et al. 2011, Hoang et al. 2017). This may 
be the reason why TMPRSS2:ERG-fusion-negative patients have poorer 
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treatment responses to androgen-deprivation therapy (Attard et al. 2009, 
2015, Graff et al. 2015).  
Marker-expression status did not stratify patients in regard to OS, which 
could be viewed as a shortcoming. OS can to some degree be considered an 
even more meaningful and significant endpoint than DSS. This is because OS 
is not susceptible to interpretation bias, whereas with DSS what is not always 
obvious is whether or not PC was the definite cause of death. When studying 
the effects of cancer treatment, OS should ideally be the end-point, because 
the aim of treatment is prolongation of life expectancy. Our study was, 
however, not an intervention trial; it was instead an observational study of the 
effects of marker expression on outcome after RP. In this setting, OS is 
therefore less relevant than DSS. 
Findings from our observational retrospective study on heterogenous 
patient cohorts can be considered hypothesis-generating only, because of its 
retrospective design and because marker expression status had no influence 
on treatment choice. Properly exploring the prognostic performance of these 
biomarkers would require prospective study settings; ideally, marker 
expression status would be determined from diagnostic biopsy.  
Based on our results, what can be speculated is that patients with 
unfavorable marker combinations may be unsuitable candidates for AS and 
should possibly opt for immediate radical therapy instead. When opting for 
immediate RT, perhaps those patients would benefit from a higher radiation 
dose, larger treatment fields, or longer adjuvant hormonal therapy after RT or 
even high-dose brachytherapy in addition to conventional RT. If unfavorable 
markers were encountered in an RP specimen, perhaps that patient would 
benefit from more intense PSA follow-up, or even immediate adjuvant RT, 
instead of salvage RT at a later stage.  
Because ERG-negative-PTEN-negative patients may have a poorer reponse 
to treatment with either conventional androgen-deprivation therapy or 
abiraterone, they may be good candidates for early administration of cytotoxic 
therapies at their hormone-naïve but metastatic stage. Furthermore, in the 
castration-resistant stage, they may possibly benefit from sequential cytotoxic 
treatments instead of novel antiandrogens. Because PTEN loss activates the 
PI3K/Akt/mTOR pathway, patients demonstrating loss of PTEN expression 
may possibly benefit from mTOR-targeted therapies–a concept currently 
studied in patients with castration-resistant PC (Statz et al. 2017).  
The main limitation of this study is its retrospective design: the fact that 
the patients’ operations took place between 1983 and 2005. It can also be 
argued that the Helsinki patient cohort was historical, as those patients treated 
in the 1980’s were diagnosed in the pre-PSA era. Because of slow disease 
progression, very long follow-up times are, however, necessary when studying 
survival outcomes of PC, especially if the outcome is DSS. The study’s 
strengths include our fairly large patient cohort and comprehensive mortality 
data. Our findings were achieved by means of IHC methods for determining 
marker expression status instead of more cumbersome techniques. This is 
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encouraging when considering assessment of marker expression status in the 
clinical practice of PC diagnosis and treatment.  
6.2 THE CHANGING NATURE OF LOCALIZED 
PROSTATE CANCER 
When deciding on appropriate treatments for localized PC today, it is virtually 
impossible to find studies of similar patients with reliable data on long-term 
outcomes. Ten to fifteen years is generally considered the minimum follow-up 
time before achievement of any meaningful conclusions about PC outcomes. 
This makes study patients inherently very different from today’s newly-
diagnosed patients, because the clinical practice in diagnosing and treating 
patients is constantly evolving. The greatest shift occurred with introduction 
of the PSA test in the 1980’s. The European Randomised Study of Screening 
for Prostate Cancer revealed that PSA screening led to PC’s being detected 
almost seven years earlier than it would have been otherwise (Finne et al. 
2010). Study cohorts of men from the pre-PSA era differ markedly from later 
ones, a fact well-known and actively mentioned especially in discussing results 
of the SPCG-4 trial (Bill-Axelson et al. 2014).  
Since the 1980’s, other modifications have occurred in the diagnostic 
process of PC, but none with such major effects as the PSA test. As one 
example, 12-core biopsies are currently standard practice, unlike 15 years ago. 
Twelve-core biopsies detect more low-volume tumors than do sextant 
biopsies, making sextant biopsies now obsolete. Strategies for sampling the 
prostate have also evolved. Instead of repeating random biopsies multiple 
times, the strategy is now actively changed even after the first round of 
negative biopsies–either to more anteriorly directed biopsies or to MRI-
targeted approaches. These biopsy practices lead to high detection rates of 
early-stage, low-volume PC, some of which will eventually receive radical 
therapies. The increasing incorporation of prostate MRI at the diagnostic stage 
concurrently leads to more MRI targeting of prostate biopsies. Because MRI 
has a high sensitivity for Gleason grade 4 and higher disease, such lesions are 
frequently targeted. This results in the overdetection of low-volume Gleason 
score 3+4 cancers that may have previously been diagnosed as Gleason score 
3+3 based on biopsies and could have been managed with AS instead of with 
radical therapies.  
The Gleason grading system has also undergone modifications that affect 
the comparability of historical patient cohorts with contemporary ones. In 
2005, the decision was that instead of reporting the most and second-most 
prevalent Gleason grade patterns in biopsy samples, the report should state 
the most common and the most dedifferentiated pattern (Epstein et al. 2005). 
Another modification entailed assigning distinct histological patterns as 
Gleason grade 4 rather than grade 3 (Epstein et al. 2005). This resulted in both 
Gleason score 6 and 7 PC constituting less aggressive disease today than prior 
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to 2005. It also remains to be seen how the most-recently introduced Grade 
grouping (Epstein et al. 2016b) will affect treatment planning. 
These changes in biopsy sampling and pathological practice have resulted 
in contemporary RP and RT cohorts representing less aggressive disease than 
did historical cohorts, even when stratifying patients by PSA level or Gleason 
score—evident in the differences between SPCG-4 and PIVOT study patients 
(Wilt et al. 2012, Bill-Axelson et al. 2014). Results from studies on historical 
cohorts must therefore be interpreted while remaining mindful of these 
differences. One way to counteract this phenomenon of RP and RT cohorts’ 
now comprising patients with less aggressive disease would be to update 
contemporary guidelines on risk stratification and AS. Allowing AS protocols 
to include a higher number of positive cores and—to a certain extent—
including Gleason grade 4 as a secondary pattern would make more patients 
eligible for AS and, consequently, reserve RP and RT as treatment choices for 
truly higher-risk disease. MRI and MRI-targeted biopsy are increasingly 
employed for AS patients. Possible undetected anterior tumors and higher-
grade tumors are therefore increasingly ruled out at the commencement of AS, 
which makes AS safer for patients compared to the situation in the pre-MRI 
era. Risk stratification could, all things considered, also include MRI findings, 
because MRI is currently routinely used in disease staging and in checking for 
clinically significant disease. 
On the other hand, so-called inverse stage migration has already been 
noticed in contemporary RP cohorts (Budaus et al. 2011, Silberstein et al. 2011, 
Bernie et al. 2014). This is a consequence of RP’s currently being offered less 
often for patients with low-risk PC, following accumulated evidence of limited 
benefit for such patients (Wilt et al. 2012, Hamdy et al. 2016). Low-risk 
patients are therefore most often offered AS. RP is also increasingly offered to 
patients with locally advanced disease as part of a multimodal-treatment 
approach (Mottet et al. 2017). 
6.3 IMPLICATIONS AND FUTURE PERSPECTIVES 
Over the period during which this thesis study took place, the diagnostic 
workup of PC has changed substantially, mainly due to the introduction of 
contemporary mpMRI and PI-RADS. The shortcomings of random biopsies in 
detecting PC, especially clinically significant cancer, and predicting disease 
location and extent are well-established. Prostate MRI has a high sensitivity 
and NPV for clinically significant PC (Moldovan et al. 2017), making it a 
promising tool for prebiopsy screening. This has now in part led to the clinical 
practice of unorganized “two-tier” screening: first, PSA screening by primary-
care doctors, and then MRI screening at the urological clinic, only after which 




Evidence is already robust that MRI targeting detects more cases of 
clinically significant PC than does a standard prostate biopsy. Due to the poor 
performance of random prostate biopsies, the need is ongoing to explore their 
replacement with MRI and MRI-targeted biopsies. This has already been 
investigated in randomized trials, but thus far with conflicting results 
(Panebianco et al. 2015, Baco et al. 2016, Porpiglia et al. 2016, Taverna et al. 
2016, Tonttila et al. 2016). 
Among the goals of such a radical shift in clinical practice would be to 
lessen harm to patients by reducing unnecessary biopsies and biopsy-related 
complications. An interesting secondary end-point—besides accuracy–in 
comparing these diagnostic strategies would be the revelation of whether 
differences exist in the occurence of post-biopsy events like infection, pain, 
and hemorrhagic complications. These should ideally be assessed by means of 
patient-reported outcome and evaluation of quality of life. The total cost of 
both diagnostic pathways, including the cost of post-biopsy complications, 
also requires calculation. The seemingly higher initial cost of the prebiopsy-
MRI approach may later balance out, because the current standard of care for 
patients with PC detected by random biopsy is to undergo prostate MRI before 
initiation of radical therapy.  
Some pathological considerations regarding the replacement of random 
biopsies with prebiopsy MRI and MRI-targeted biopsies are as yet 
unanswered. In a hypothetical trial comparing the two strategies, many 
patients with significant PC in either arm would advance to RP, which would 
then offer the opportunity to compare the performance of random versus MRI-
targeted biopsy in predicting disease location and aggressiveness. Presumably 
there would be less upgrading and downgrading of disease in the prebiopsy-
MRI arm, but there exists as yet scant evidence to support this hypothesis. 
MRI targeting would most likely also perform better than random biopsy in 
detecting the index tumor in the prostate, the index tumor’s being the most 
dedifferentiated and often the largest. 
Incorporating the study of tissue markers would be an additional 
interesting aspect. Prospective assessment of marker expression, such as for 
ERG and PTEN, both from diagnostic biopsies and from RP specimens, would 
allow comparison of the ability of MRI-targeted and random biopsies to detect 
unfavorable marker expression in PC foci. Tissue marker expression in MRI-
targeted biopsies has thus far lacked much intensive study.  
To assess whether the diagnostic approach of prebiopsy MRI followed by 
MRI-targeted biopsies results in improved risk stratification, the clinical 
outcomes of treated patients would also require analysis. An immediate end-
point would be, for those patients undergoing RP, unfavorable pathological 
outcomes such as seminal-vesicle invasion, extraprostatic extension, and 
positive surgical margin; these could be compared between trial arms. 
Intermediate end-points could be discontinuation of AS, biochemical 
recurrence, and requirement of secondary therapy after RP and RT, plus 
clinical disease progression such as metastases. Long-term results like OS and 
 
81 
DSS would likely require very extensive follow-up, 10 years at a minimum, to 
show differences between trial arms. 
Total incidence rates of PC in developed countries are currently not rising 
(Finnish Cancer Registry 2016, Hoffman et al. 2016). This is likely due to the 
substantial number of cases already diagnosed during the “heydays” of 
organized and unorganized PSA screenings and due to doctors’ improved 
awareness of the adverse effects of screening today. The PSA test is, 
nonetheless, here to stay. Doubtlessly, the prevailing clinical practice, in 
which, without recommendations for PC screening, PSA screening is 
arbitrarily offered to unselected men, is unsatisfactory for precise detection of 
clinically significant PC.  
As screening is now less frequent, PC incidence, diagnosed at the metastatic 
stage, has started rising again, at least in 50- to 69-year-old US men based on 
SEER registry data (Hoffman et al. 2016). It is therefore possible that 
screening for PC, perhaps with a combination of PSA and genetic markers, will 
someday make a comeback. In light of this, it is especially important to 
optimize diagnostic processes and risk stratification in order to avoid 
overdetection and overtreatment of low-risk PC and to detect in time 




1) The average annual incidence of bacteremic complications following 
transrectal biopsies was 0.7%, with a trend toward a rising incidence 
observable. No clinical risk factor for bacteremias was identifiable. 
Recent international travel significantly raised the risk for developing 
bacteremia from an FQ-resistant organism. Patients with recent travel 
abroad should be candidates for alternative antibiotic prophylaxis or, 
following rectal swabs and fecal cultures, for tailored prophylaxis. 
Reduction in unnecessary biopsies and in biopsy-related infections calls 
for development of new strategies. 
2) Twelve-core transrectal biopsies predicted the locations and extent of 
PC tumors in RP specimens unreliably and would have performed 
poorly in planning of focal therapies. Planning of radical therapies is 
currently based on findings from prostate MRI. Positive surgical 
margins and extraprostatic extension at RP mostly resulted from the 
index tumor, supporting the rationale of designating the index tumor 
based primarily on its degree of dedifferentiation instead of on tumor 
size. 
3) Prostate MRI had limitations when serving as a follow-up tool in the AS 
of PC. Low-volume, low-grade PC was visible on MRI for only half the 
patients. Without standardized imaging and reporting protocols such as 
PI-RADS, prostate MRI does not add value to the diagnosis and follow-
up of PC patients.  
4) Loss of PTEN expression appeared to be a strong driver of disease 
progression, leading to shorter DSS times and after RP, shorter survival 
time free of secondary therapy. The subpopulation of patients with the 
poorest outcomes had cancers that were ERG-fusion negative and 
PTEN negative with high levels of AR expression. The prognostic 
performance of PTEN loss should be investigated further in 
prospective-study settings.  
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